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ABSTRACT 
 
OBJECTIVE – Oxidative stress increases flux through the hexosamine biosynthetic pathway 
(HBP) resulting in greater O-GlcNAcylation of target proteins.  Since increased oxidative stress 
and HBP flux are associated with insulin resistance, we hypothesized that its activation leads to 
greater O-GlcNAcylation of BAD (pro-apoptotic) and increased myocardial apoptosis.   
 
RESEARCH DESIGN AND METHODS – To investigate our hypothesis, we employed two 
experimental models: 1) H9c2 cardiomyoblasts exposed to high glucose (33 mM glucose) ± HBP 
modulators ± antioxidant treatment vs. matched controls (5.5 mM glucose); and 2) a rat model of 
high fat diet-induced insulin resistance and hyperglycemia. We evaluated apoptosis in vitro by 
Hoechst nuclear staining, Annexin-V staining, caspase activity measurements and 
immunoblotting while in vivo apoptosis was assessed by immunoblotting. In vitro reactive 
oxygen species (ROS) levels were quantified by H2DCFDA staining (fluorescence microscopy, 
flow cytometry). We determined overall and BAD O-GlcNAcylation, both by immunoblotting 
and immunofluorescence microscopy.  As BAD-Bcl-2 dimer formation enhances apoptosis, we 
performed immunoprecipitation analysis and immunofluorescence microscopy (co-localization) 
to determine BAD-cl-2 dimerization. In vivo overall O-GlcNAcylation, BAD O-GlcNAcylation 
and BAD-Bcl-2 dimerization was determined by immunoprecipitation and immunoblotting. 
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RESULTS – High glucose treatment of cells significantly increased the degree of apoptosis as 
revealed by Hoechst nuclear staining (54 ± 9%, p<0.01 vs. 5.5 mM), Annexin-V staining (43 ± 
5%), caspase activity assay (26 ± 2%) and immunoblotting.  In parallel, overall O-
GlcNAcylation (p<0.001 vs. 5.5 mM), BAD O-GlcNAcylation (p<0.05 vs. 5.5 mM) and ROS 
levels were increased (fluorescence microscopy – p<0.05 vs. 5.5 mM; flow cytometry – p<0.001 
vs. 5.5 mM).  HBP inhibition using DON and antioxidant treatment (α-OHCA) attenuated these 
effects while HBP activation by PUGNAc exacerbated it. Likewise, insulin resistant rat hearts 
exhibited significantly higher caspase-3 (p<0.05 vs. controls), overall O-GlcNAcylation (p<0.05 
vs. controls) and BAD O-GlcNAcylation levels (p<0.05 vs. 5.5 mM). BAD-Bcl-2 dimer 
formation was increased in cells exposed to hyperglycemia [immunoprecipitation analysis and 
co-localization] and in insulin resistant hearts.  
 
CONCLUSIONS - Our study identified a novel pathway whereby hyperglycemia results in 
greater oxidative stress, resulting in increased HBP activation and increased BAD O-
GlcNAcylation.  We also found greater BAD-Bcl-2 dimerization increasing myocardial 
apoptosis, suggesting that this pathway may play a crucial role in the onset of the diabetic 
cardiomyopathy.   
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UITTREKSEL 
 
DOELWIT – Oksidatiewe stres verhoog fluks deur die heksosamien biosintetiese weg (HBW) 
wat in „n groter O-GlcNAsetilering van teiken proteïene resulteer.  Weens die feit dat verhoogde 
oksidatiewe stres en HBW fluks verband hou met insulienweerstandigheid, hipotetiseer ons dat 
die aktivering hiervan tot groter O-GlcNAsetilering van BAD (pro-aptoptoties) en verhoogde 
miokardiale apoptose lei.   
 
NAVORSINGS ONTWERP EN METODES – Om die hipotese te ondersoek het ons twee modelle 
ontplooi: 1) H9c2 kardiomioblaste is blootgestel aan hoë glukose konsentrasie (33mM glucose) ± 
HBW moduleerders ± antioksidant behandeling vs. gepaarde kontrole (5.5mM glucose); en 2) „n 
hoë vet dieetgeïnduseerde insulienweerstandige rotmodel en hiperglukemie.  Ons het apoptose in 
vitro deur middel van Hoescht nukleuskleuring geëvalueer, kasapase aktiwiteit bepalings en 
immunoblotting terwyl apoptose in vivo getoets is deur immunoblotting.  Reaktiewe 
suurstofspesie (RSS) vlakke is deur middel van H2DCFDA verkleuring (fluoresensie 
mikroskopie, vloeisitometrie) bepaal.  Algehele en BAD O-GlcNAsetilering is beide deur 
immunoblotting en immunofluoresensie mikroskopie bepaal.  BAD-Bcl-2 dimeervorming 
bevorder apoptose, om BAD-cl-2 dimerisasie te bepaal is daar van immunopresipitering analise 
en immunofluoresensie mikroskopie (ko-lokalisasie) gebruik gemaak.  In vivo is algehele O-
GlcNAsetiliering, BAD O-GlcNAsetiliering en BAD-Bcl-2 dimerisasie deur immunopresipitasie 
en immunoblotting bepaal.   
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RESULTE – Hoë glukose behandeling van selle het die graad van apotpose betekenisvol verhoog 
soos blootgelê deur Hoechst nukleuskleuring (54 ± 9%, p<0.01 vs. 5.5 mM), Annexin-V kleuring 
(43 ± 5%), kaspase aktiviteit assay (26 ± 2%) en immunoblotting.  In parallel, algehele O-
GlcNAsetilering (p<0.001 vs. 5.5 mM), BAD O-GlcNAsetilering (p<0.05 vs. 5.5 mM) en RSS 
vlakke is verhoog (fluoresensie mikroskopie– p<0.05 vs. 5.5 mM; vloeisitometrie– p<0.001 vs. 
5.5 mM).  HBW inhibering deur van DON en van antioksidant behandeling gebruik te maak (α-
OHCA) het hierdie effekte verlaag terwyl HBW aktivering deur PUGNAc dit verhoog het. 
Netso, het insulienweerstandige rotharte betekenisvolle hoë kaspase -3 (p<0.05 vs. kontrole), 
algeheel O-GlcNAsetilering (p<0.05 vs. kontrole) en BAD O-GlcNAsetiliering vlakke (p<0.05 
vs. 5.5 mM) getoon. BAD-Bcl-2 dimeervorming is verhoog in hiperglukemies blootgestelde selle 
[immunopresipitering analise en ko-lokalisering] en in insulienweerstandige harte.   
 
GEVOLGTREKKINGS – Ons studie het „n nuwe weg geïdenifiseer waar hiperglukemie in groter 
oksidatiewe stres resulteer wat weer HBW aktivering verhoog en BAD O-GlcNAsetilering 
verhoog het.  Ons het verder bevind dat groter BAD-Bcl-2 dimerisasie miokardiale apoptose 
verhoog wat voorstel dat hierdie weg „n belangrike rol in diabetiese kardiomiopatie speel.   
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(Laghu nyaasam, 500 BCE.) 
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Type 2 diabetes mellitus (T2DM) is one of the most rapidly emerging global health challenges of 
the 21
st
 century and a major cause of premature death. For example, ~ every  10 seconds a person 
dies from diabetes-related causes, and death rates are predicted to rise by ~ 25% during the next 
decade [1]. Recent data released by the International Diabetes Federation (IDF) show that more 
than 230 million people, almost 6% of the world's adult population, now live with diabetes. 
Moreover, it is estimated that the number of individuals affected by diabetes will increase from 
135 million in 1995 to 300 million by 2025 [1, 2], while the World Health Organization (WHO) 
extends this estimate to ~366 million by 2030 [3, 4].  
Compounding the problem is statistics showing that the metabolic syndrome (a pre-diabetic 
condition) is also very common, with an approximate 65 million individuals in the United States 
affected [5]. Metabolic syndrome is a cluster of metabolic abnormalities which is strongly 
associated with the risk of development of both T2DM and cardiovascular diseases (CVD). It is 
characterized by impaired glucose metabolism, dyslipidaemia, hypertension and obesity [6]. 
Hence the metabolic syndrome equals a pre-diabetic condition that could manifest as T2DM at a 
later stage, therefore meaning that future projections of T2DM may even be higher than present 
estimates [7]. Moreover, this is likely to increase further as obesity and sedentary lifestyles 
become more endemic in younger populations. Similarly, developing nations are also at 
increased risk for higher T2DM incidences and associated burdens of disease, e.g. CVD. It is 
currently estimated that ~19 million individuals in India are affected by T2DM, which is likely to 
triple by 2025 [7]. Such increases will place a significant burden on developing countries such as 
India and South Africa. The reasons for this escalation may include a rapidly changing lifestyle 
and/or greater aging of these populations. Moreover, low birth weight due to poor nutritional 
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intake in developing countries is also proposed to increase the likelihood of developing T2DM 
during adulthood [7]. 
 
1.1 CARDIOVASCULAR COMPLICATIONS ASSOCIATED WITH T2DM 
 
Diabetes causes several cardiovascular complications that are the major cause of mortality 
associated with this condition [8-10]. For example, diabetes may be responsible for a range of 
complications such as increased atherosclerosis in large arteries (carotids, aorta, and femoral 
arteries) and also lesser ones e.g. coronary arteries [11] -these are classed as macrovascular and 
microvascular. This increases the risk for myocardial infarction, stroke, and limb loss [12]. 
Micro-angiopathy may also contribute to retinopathy and renal failure, and cardiac pathology [2, 
13, 14]. In addition to angiopathy, T2DM can affect cardiac structure and function in the absence 
of changes in blood pressure and coronary artery disease, a condition referred to as the diabetic 
cardiomyopathy. Here altered fuel substrate metabolism is strongly implicated in this process 
[15].  
Mortality from heart disease is ~ 2 to 4-fold higher in diabetic patients when compared to non-
diabetics with the same magnitude of vascular diseases [16]. Moreover, diabetic cardiomyopathy 
can occur without any vascular pathogenesis [16, 17]. The epidemiological link between diabetes 
mellitus and the development of heart failure (HF) [18], independent of atherosclerotic 
cardiovascular disease is well established. These studies show a higher risk of HF in diabetic 
patients after considering age, blood pressure, weight, cholesterol and the history of coronary 
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artery disease [19-21]. Indeed, the Framingham Heart Study showed that the frequency of HF is 
2.4-fold and 5-fold higher in diabetic men and women, respectively. Age also plays a role, i.e. 
for elderly diabetic patients the prevalence of HF was as high as 30% [18].   
The risk of developing HF is also associated with stress-induced increases in plasma glucose 
levels [22]. For example, the development of HF was predicted by insulin resistance (IR) in 
individuals prospectively assessed over a 9-year period. Moreover, one standard deviation 
decrease in insulin sensitivity increases the risk of HF by approximately one third [23]. This 
robust association is largely due to the prevalence of elevated blood pressure, high blood sugar 
levels and associated free radical generation [24], microvascular dysfunction, and ischemic heart 
disease in IR states [25]. These studies therefore point towards a strong link between T2DM and 
the onset of heart diseases and necessitate a thorough understanding of underlying mechanisms 
driving this process. However, to recognize the diabetic cardiomyopathy as a distinct entity 
raises the hypothesis that altered metabolism and IR may have a detrimental effect(s) on the 
myocardium [21, 25-31]. Since metabolic alterations may play a crucial role in this process, and 
the emphasis of this thesis is on hyperglycaemia, the focus will now be on the important aspects 
of a) glucose and b) fat metabolism of the heart. 
Under conditions of perturbed glucose and fat metabolism, e.g. hyperglycaemia, there are 
downstream effects on oxidative phosphorylation and  the activation of alternative glucose 
utilizing pathways such as pentose phosphate pathway, polyol pathway, and the hexosamine 
biosynthetic pathway Together these factors conspire and  play a crucial role in mediating 
detrimental effects of hyperglycaemia on heart.  These aspects will be further  discussed in the 
following sections. 
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1.2 GLUCOSE METABOLISM – A PRIMER 
 
Glycogen stores and exogenous glucose supply are the main sources of glycolytic substrates. The 
heart‟s glycogen pool is comparatively small, i.e. ~30 µmol/g wet weight compared to ~150 
µmol/g wet weight in skeletal muscle [15, 32] and is rapidly turned over despite constant tissue 
concentrations [33]. Greater supply of exogenous fuel substrates and/or hyperinsulinemia can 
eventually lead to increased glycogen storage [34-36]. Conversely, adrenergic stimulation, 
decreased myocardial ATP levels and elevated inorganic phosphate levels e.g. during ischaemia 
or intense exercise [34, 37, 38], activates glycogenolysis thereby promoting increased glycolytic 
flux (Figure 1.1). 
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Figure 1.1:  A representation of exogenous and intracellular sources of glucose.  
 
Glucose transport into cells is regulated by the transmembrane glucose gradient and the number 
of glucose transporters (GLUTs) present on the sarcolemma. For cardiomyocytes, GLUT-4 is the 
major transporter, with GLUT-1 to a lesser extent. GLUT-4 resides within intracellular vesicles 
and is translocated to the sarcolemma in response to insulin stimulation, exercise or ischaemia 
[34, 39, 40] thereby enhancing glucose uptake (Figure 1.2). 
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Figure 1.2:  Insulin and AMPK regulate GLUT-4 translocation and myocardial glucose uptake. 
 
GLUT-4 translocation can also be stimulated by AMP-activated protein kinase (AMPK), for e.g. 
response to ischaemia [41] or exercise [39, 41, 42]. Moreover, mice expressing cardiac-specific 
dominant negative AMPK, exhibit lower rates of glucose transport [42], further supporting a role 
for AMPK in myocardial glucose uptake. In agreement, Russell et al. [43] also found that 
transgenic mice expressing inactive AMPK display normal GLUT-4 expression, baseline and 
insulin-stimulated cardiac glucose uptake, but fail to increase glucose uptake and glycolysis 
during ischaemia [43]. This study demonstrates a key role for AMPK in mediating insulin-
independent and also stress-induced glucose uptake. The role of AMPK in regulating glycogen 
content in heart has also come to the fore in recent years [42, 44, 45]. Inactive AMPK with a 
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mutation in its regulatory subunit showed an association with glycogen accumulation and 
hypertrophic cardiomyopathy [44, 46, 47]. In contrast, acute activation of AMPK activates 
glycogenolysis thereby increasing glycolytic substrate supply [48, 49].  
 
 
Exogenous glucose uptake and glucose derived from glycogenolysis eventually feed into 
glycolysis. Phosphofructokinase-1 (PFK-1) is a regulatory enzyme that catalyzes the first 
irreversible step in glycolysis, i.e. converting fructose 6-phosphate to fructose 1,6-bisphosphate 
(Figure 1.3). This step requires 1x ATP and its breakdown products are important regulators of 
PFK-1, i.e. ATP inhibits it while it is activated by ADP, AMP and inorganic phosphate. Hence 
when intracellular phosphorylation potential is low, flux through glycolysis can be increased.  
AMPK activates PFK-2 [50, 51] by phosphorylation, and the fructose 2,6-bisphosphate formed 
can also activate PFK-1 [38, 52]. The enzyme aldolase then converts fructose-1,6-bisphosphate 
to glyceraldehyde-3-phosphate. Glyceraldehyde-3-phosphate dehydrogenase (GAPDH) converts 
glyceraldehyde-3-phosphate to 1,3-diphosphoglycerate, producing NADH. GAPDH is an 
important regulatory step in the glycolytic pathway. Here NADH accumulation within the 
cytoplasm inhibits GAPDH while NAD
+
 increases its activity [53]. The regeneration of NAD
+
 
from NADH is inhibited by lactate and 1,3-diphosphoglycerate.  
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Figure 1.3:  A schematic representation of the glycolytic pathway and the various regulators of the 
pathway. PFK-1 is regulated by the ADP/ATP ratio and fructose-2,6-bisphosphate levels. PFK-2 is 
activated by AMPK. Glyceraldehyde-3-phosphate dehydrogenase is regulated by the NAD
+
/NADH ratio. 
 
The glycolytic pathway converts glucose 6-phosphate to pyruvate reducing NAD
+
 to NADH and 
generates 2x ATP per glucose molecule. The NADH and pyruvate formed as a result of 
glycolysis are either diverted to the mitochondrial matrix to generate CO2 and NAD
+
 that 
completes the aerobic oxidation process, or the pyruvate is converted to lactate and NAD
+
 in the 
2 x ADP 
2 x ATP 
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cytosol (non-oxidative glycolysis). The myocardium produces net lactate only under conditions 
like diabetes [54-56] or ischaemia [34, 57, 58]. Pyruvate formed at the end of glycolysis has 
three major fates: 1) conversion to lactate, 2) carboxylation to oxaloacetate or malate and 3) 
decarboxylation to acetyl-CoA.   
 
1.3 FATTY ACID METABOLISM – A PRIMER 
 
1.3.1 Exogenous fatty acid uptake 
 
Myocardial fatty acid uptake is largely determined by plasma free fatty acids (FFA) availability 
[59-61]. FFA levels can vary up to four-fold during the course of a day in humans (~0.2 to 0.8 
mM), while under conditions of metabolic stress for e.g. ischaemia, diabetes or starvation it can 
be significantly increased (~1.0 mM) [62]. FFA are transported in non-esterified form attached to 
albumin, covalently bound to triglyceride contained within chylomicrons, or very low density 
lipoproteins (VLDL) [60] which are hydrolysed by lipoprotein lipase on the cardiomyocytes [63-
66].  
FA are taken in by cardiomyocytes via passive diffusion or by protein-mediated transport across 
the sarcolemma [67]. The latter is mediated by fatty acid translocase (FAT) or plasma membrane 
fatty acid binding protein (FABPpm) [67-69] (Figure 1.4). CD36 is a specific 88 kDa FAT protein 
that is abundantly expressed in cardiac and skeletal muscle and is the predominant FAT form in 
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the heart [67, 68]. CD36 also partially regulates myocardial fatty acid uptake in humans [70]. 
FFA bind to FABP and are esterified to fatty acyl-CoA by fatty acyl-CoA synthase (FACS). 
Recent studies show that there are CD36-associated FABP and FACS proteins in the cytosol, 
therefore meaning that transported FA can immediately be esterified to fatty acyl-CoA [68]. 
Intriguingly, some studies found that there is translocation of FAT/CD36 from an intracellular 
location to the sarcolemma in response to contraction, increased energy demand [71-73] and also 
to insulin stimulation [73]. However, these responses need to be confirmed under physiologically 
relevant conditions. 
 
 
 
 
Figure 1.4: Fatty acid transport into the cell. FA enter the cardiomyocyte by either passive diffusion or 
protein-mediated transport through the sarcolemma via plasma membrane fatty acid binding protein 
(FABPpm) or CD36/fatty acid translocase (FAT). The FA are then esterified by the actions of fatty acyl-
CoA synthase (FACS) and are now ready to enter mitochondria to undergo β-oxidation. VLDL- very low 
density lipoprotein.  
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1.3.2 Mitochondrial fatty acid uptake 
 
Fatty acid β-oxidation mainly occurs in mitochondria [74, 75]. Long-chain acyl-CoAs must be 
transported into the mitochondria by specific carriers since the inner mitochondrial membrane is 
relatively impermeable. This transport is carried out by a carnitine-dependent transport system 
[59, 76], i.e. carnitine palmitoyl transferase – 1 (CPT-1) which catalyzes formation of long-chain 
acylcarnitine from long-chain fatty acyl-CoA in the intermembrane space of mitochondria; the 
carnitine acyltranslocase that transports long-chain acylcarnitine across the inner mitochondrial 
membrane; and finally carnitine palmitoyltransferase- 2 (CPT-2) that regenerates long-chain 
acyl-CoA within the mitochondrial matrix (Figure 1.5).  
CPT-1 is the key regulatory step of mitochondrial fatty acid uptake [59, 76] and has two 
isoforms: CPT-1α enriched in the liver and CPT-1β in the heart [77, 78]. CPT-Iβ is 30-fold more 
sensitive than CPT-1α and is also more strongly inhibited by malonyl-CoA than CPT-1α [77-79]. 
Malonyl-CoA strongly inhibits CPT-1 by binding to its cytosolic side [76, 77, 80], thus a key 
regulator of mitochondrial fatty acid oxidation decreased malonyl-CoA levels increase its uptake 
and oxidation [81-83] while increased levels result in the reverse effect [84, 85]. Malonyl-CoA 
has a rapid turnover in the heart [86, 87] and is formed from acetyl-CoA by acetyl-CoA 
carboxylase [88]. AMPK activation results in increased fatty acid oxidation by inhibiting ACC 
and thereby reducing malonyl-CoA levels [89, 90].  
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Figure 1.5: Mitochondrial fatty acid transport. Fatty acyl-CoAs are shuttled into the mitochondria by 
CPT-1 (carnitine palmitoyl transferase-1) that converts it to acyl-carnitine. Carnitine acyl translocase 
(CAT) then transports it through the inter-mitochondrial space to CPT-2 where the long-chain fatty acyl-
CoA is regenerated inside the mitochondrial matrix. (FAT= Fatty acid translocase.) 
 
Once taken up by mitochondria, long-chain fatty acyl-CoA undergoes β-oxidation, a process that 
sequentially cleaves off acetyl-CoA units and generating reducing equivalents (NADH and 
FADH2) in the process. The β-oxidation spiral involves four reactions i.e. acyl-CoA 
dehydrogenase, 2-enyl CoA hydratase, 3-hydroxyacyl CoA dehydrogenase, and the last reaction 
catalyzed by 3-ketoacyl CoA thiolase (3-KAT). Reducing equivalents that are generated can then 
undergo oxidative phosphorylation to generate ATP [59]. 
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1.4 MITOCHONDRIAL OXIDATIVE PHOSPHORYLATION 
 
Oxidative phosphorylation involves the flow of electrons through the electron transport chain, 
i.e. from electron donors such as NADH and FADH2 to the final electron acceptors. The electron 
transport chain consists of complexes I - IV located within the inner membrane of the 
mitochondrion [91] (Figure 1.6). NADH-coenzyme Q oxidoreductase, also known as NADH 
dehydrogenase or complex I, is the first protein in the electron transport chain [92]. Complex I 
binds to flavin mononucleotide (FMN), and is immediately re-oxidized to NAD. NAD is 
"recycled," acting as an energy shuttle. FMN receives a proton from NADH and also picks up a 
proton from the matrix. In this reduced form, it passes the electrons to iron-sulfur clusters that 
are part of the complex, and forces two protons into the intermembrane space [92]. This is the 
only enzyme that is part of both the citric acid cycle and the electron transport chain [93, 94].  
Q-cytochrome c oxidoreductase is also known as cytochrome c reductase, cytochrome bc1 
complex, or simply complex III [95, 96]. Protons are transferred to this complex from an 
intermediate Coenzyme Q. The movement of protons from Coenzyme Q to complex III is a 
proton translocation event. Cytochrome c oxidase, also known as complex IV, is the final protein 
complex in the electron transport chain [97]. More protons are translocated by Complex IV, and 
it is at this site that oxygen binds along with protons. Using the electron pair and remaining free 
energy, oxygen is reduced to water. Since molecular oxygen is diatomic, it actually takes two 
electron pairs and two cytochrome oxidase complexes to complete the reaction sequence for the 
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reduction of oxygen. This last step in electron transport serves the critical function of removing 
electrons from the system so that electron transport can operate continuously [98]. The enzymes 
in the electron transport system use the energy released from the oxidation of NADH to pump 
protons across the inner membrane of the mitochondrion thereby generating an electrochemical 
gradient. The potential energy stored is then used by ATP synthase to produce mitochondrial 
ATP. Succinate-Q oxidoreductase, also known as complex II or succinate dehydrogenase, is a 
second entry point to the electron transport chain [99]. 
 
 
 
Figure 1.6: A schematic representation of the electron transport chain and complexes. 
 
After discussing the essential features of glucose and fatty acid metabolism, it is important to 
note that these two major catabolic pathways are inter-related in terms of its utilization. This 
phenomenon was first described by Philip Randle during the 1960s [100].  
37 
 
1.5 RANDLE CYCLE 
 
The basic premise is that elevated glucose concentrations stimulate pancreatic insulin secretion 
that subsequently attenuates FFA release from adipose tissue. Thus, glucose utilization is 
stimulated by insulin, unaffected by high fatty acid concentrations [100]. However, when 
glucose and insulin concentrations are low, FA become the major fuel substrate for skeletal and 
cardiac muscle [100]. Under conditions of high FA oxidation, there is an increased yield of 
acetyl-CoA, citrate and NADH levels. Increased levels of citrate inhibit PFK, thus attenuating 
glycolysis. Furthermore, increased acetyl-CoA and NADH levels inhibit PDH thereby decreasing 
glucose oxidation [101]. The inhibition of PDH and PFK results in accumulation of upstream 
glycolytic metabolites, e.g. glucose 6-phosphate that inhibits hexokinase thereby also lowering 
glycolytic flux. Hence at higher fatty acid oxidation rates, there is reduced glucose oxidation and 
vice versa [100] (Figure 1.7). However, Shulman‟s laboratory [102]  challenged this hypothesis 
since  they observe decreased intramuscular glucose 6-phosphate levels under conditions of fat-
induced insulin resistance. Moreover, fat accumulation interferes with the GLUT4 transporter 
activity and/or hexokinase II activity.  
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Figure 1.7: The glucose-fatty acid cycle (Randle cycle) in muscle. Fatty acid oxidation attenuates 
pyruvate dehydrogenase (PDH) and glucose oxidation, while citrate diminishes phosphofructokinase 
(PFK) and glycolysis. 
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1.6 THE HEART AND PERTURBED METABOLISM 
1.6.1 Myocardial ischaemia 
Mitochondrial oxidative metabolism is critically dependent on oxygen supply to the heart, and its 
curtailment results in attenuated mitochondrial ATP production and decreased function [16]. An 
initial adaptive response is to increase glycolysis, allowing for glycolytic ATP production that is 
useful to maintain intracellular ionic homeostasis [20]. However, due to ischemic shock the heart 
is also exposed to high concentrations of FFA [16, 102]. In addition, AMPK is activated to 
enhance glucose uptake. However, AMPK activation also increases fatty acid oxidation. Thus, 
counter-intuitively, fatty acid oxidation becomes the main residual source of mitochondrial 
oxidative metabolism during ischaemia-reperfusion [62].  As a result of the Randle cycle higher 
FA oxidation diminishes glucose oxidation causing a “de-linking” between higher glycolysis 
rates and lower glucose oxidation [14]. Interestingly, clinical therapy that improves the coupling 
of glycolysis to glucose oxidation can reduce myocardial tissue acidosis and lactate build-up, 
thereby blunting functional recovery in response to ischaemia-reperfusion[103].  
 
1.6.2 Diabetic heart 
 
Altered myocardial substrate and energy metabolism is an important contributing factor to the 
development of the diabetic cardiomyopathy [104, 105]. With T2DM, carbohydrate metabolism 
is usually reduced and FA metabolism enhanced [54, 106]. Despite increased FA utilization by 
the diabetic heart, its FA uptake exceeds FA oxidation rates thereby resulting in intracellular 
myocardial lipid accumulation [107-109] (Figure 1.8). Lipid intermediates like ceramides may 
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promote apoptosis in cardiomyocytes thus leading to cardiac dysfunction, a phenomenon known 
as “lipotoxicity” [110].  
 
 
Figure 1.8:  Alterations in cardiac energy metabolism in the obese heart. FA and carbohydrates are 
the key sources of energy supply for the heart. With obesity, a switch in energy metabolism occurs such 
that FA becomes the more prominent source of acetyl-CoA for the tricarboxylic acid cycle. FAT indicates 
fatty acid transporter; PDH, pyruvate dehydrogenase; MCT, monocarboxylate carrier; GLUT, glucose 
transporter. 
 
Mitochondrial substrate oxidation results in production of reducing equivalents like NADH and 
FADH2 which enter the electron transport chain that generates an electrochemical proton 
gradient across the mitochondrial membrane to drive ATP synthesis. In perfectly coupled 
mitochondria, there is no proton “leak” across the mitochondrial membrane, i.e. the entire 
gradient is utilized for ATP synthesis. However, under baseline conditions some proton leak 
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occurs with uncoupling proteins (UCPs) providing a mechanism whereby protons re-enter the 
mitochondrial matrix [111]. 
There is evidence that fatty acid-mediated uncoupling reduces cardiac efficiency in the diabetic 
heart [112]. Studies have shown that with  obesity, there is elevated UCP2 expression and with 
high circulating fatty acids there is increased UCP 3 mRNA synthesis [113].  Thus higher UCP 
levels may promote uncoupling of mitochondrial oxidative phosphorylation meaning that  ATP 
production and cardiac efficiency may  be compromised [113]. Increased superoxide production 
is another potential activator of UCPs in the diabetic heart. Here UCPs are activated to limit the 
production of ROS by reducing the mitochondrial membrane potential [114]. However, higher 
FA utilization increases delivery of reducing equivalents to the electron transport chain, 
elevating superoxide production and resulting in greater mitochondrial uncoupling. The higher 
uncoupling results in attenuated mitochondrial ATP production and reduced contractile function 
with diabetes [115].  
To sum up, high FFA and glucose supply in the bloodstream is purposed to result in detrimental 
consequences for the diabetic heart (Figure 1.9) [104]. Increased FFA supply enhances FA 
oxidation that may lead to mitochondrial uncoupling [115]. Moreover, FA supply exceeds FA 
oxidation rates leading to intracellular lipid accumulation, higher ceramide levels and increased 
apoptosis or “lipotoxicity” [2]. High FA supply also has gene effects, i.e. FAs are ligands for 
peroxisome proliferator-activated receptor-α (PPARα), a key transcription factor regulating 
several FA metabolic genes, thus further elevating FA oxidation rates [116]. PPARα also induces 
expression of PDK4, a negative regulator of PDH [116], thereby leading to reduced glucose 
uptake and oxidation. High glucose levels also have several deleterious effects mediated via 
elevated ROS production (this will be discussed later in the thesis - Section 1.7). 
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Figure 1.9: Potential contributors to the development of diabetic cardiomyopathy. Increased FFA 
activates PPARα signaling, leading to increased transcription of genes involved in FA oxidation. 
Increased delivery of FA decreases insulin sensitivity and activates transcriptional pathways like PPARα. 
PPARα activation reduces glucose oxidation by increasing pyruvate dehydrogenase kinase 4 (PDK4) 
expression increasing CD36 expression. Another PPARα target malonyl-CoA decarboxylase (MCD), 
degrades malonyl-CoA. This stimulates CPT-1 thereby increasing FA uptake by the mitochondrion. Other 
PPARα target genes include medium- and long-chain acyl CoA dehydrogenase and hydroxyl acyl CoA 
dehydrogenase. Eventually this leads to increased ROS, ceramide and AGEs, lipotoxicity, glucotoxicity, 
apoptosis and reduced cardiac efficiency. TG indicates triglycerides; GLUTs- glucose transporters; PDK4- 
pyruvate dehydrogenase kinase 4; MCD- malonyl-coenzyme A decarboxylase; MCoA- malonyl-coenzyme 
A; ACoA- acetyl-coenzyme A; ACC- acetyl coenzyme A carboxylase; CPT1- carnitine palmitoyl-
transferase 1; PDH- pyruvate dehydrogenase; CE- cardiac efficiency; PKC- protein kinase C; and AGE- 
glycation end products. Modified from [2]. 
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1.7 OXIDATIVE STRESS AND DIAETIC COMPLICATIONS 
 
Production of increased amounts of reactive oxygen species is known to have detrimental effects 
on  cellular function [117].  Oxidative stress is caused by an imbalance between the production 
of reactive oxygen and the organism‟s innate  ability to  deactivate reactive intermediates and/or 
easily repair the resulting damage. This may  occur under conditions of higher substrate influx, 
e.g. hyperglycaemia and/or hyperlipidaemia [118]. While high glucose conditions increase 
superoxide production, high fat levels elevate peroxynitrite and superoxide production. 
It is known that increased oxidative stress participates in the development and progression of 
diabetes and its complications [118-120]. The proposed mechanisms of oxidative stress-mediated 
diabetic complications include activation of transcription factors, advanced glycation end 
products (AGE) and protein kinase C (PKC).  
Excess free radicals damage cellular proteins, membrane lipids and nucleic acids and eventually 
cause cell death. Glucose oxidation is a major source of free radical production [121]. Glucose 
(enediol form) is oxidized in a transition metal-dependant reaction to an enediol radical anion 
which is then converted to reactive ketoaldehydes and superoxide anion radicals [121]. The latter 
then undergoes dismutation to form hydrogen peroxide degraded by catalase or glutathione 
peroxidase (Figure 1.10).  
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Figure 1.10: Production of free radicals. 
 
However, if hydrogen peroxide is not degraded it can form extremely reactive hydroxyl radicals 
in the presence of transition metals [121, 122]. In addition, superoxide anion radicals can also 
react with nitric oxide forming reactive peroxynitrite radicals [121-126]. Under hyperglycaemic 
conditions, lipid peroxidation of low density lipoproteins (LDL) is also promoted by a 
superoxide-dependent pathway that generates free radicals [127, 128].  
ROS may damage cells by the inhibition of GAPDH, a key glycolytic enzyme. Here increased 
ROS levels result in apoptosis by causing DNA strands to break, leading to poly (ADP-ribose) 
polymerase (PARP) activation. PARP then ADP-ribosylates GAPDH, thereby attenuating 
glycolysis [129]. Subsequently, glucose is routed through other glucose-utilizing pathways like 
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the polyol pathway, pentose phosphate pathway and the hexosamine biosynthetic pathway which 
will now be discussed in more detail. 
 
1.8 HYPERGLYCAEMIA ACTIVATES ALTERNATE METABOLIC 
PATHWAYS 
 
1.8.1 Polyol pathway 
 
 
 
Figure 1.11: Hyperglycaemia increases flux through the polyol pathway. Reproduced and modified 
from [130]. GSSG: Glutathione; GSH: Reduced gluthathione; SDH: Sorbitol dehydrogenase. 
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Aldose reductase is a key enzyme in the polyol pathway that reduces toxic aldehyde into inactive 
alcohols (Figure 1.11) [131]. However, with diabetes-induced hyperglycaemia, aldolase 
reductase reduces glucose to sorbitol that is later oxidized to fructose. As a result, aldolase 
reductase uses up reducing equivalents (NADPH) [132]. Since NADPH is also needed for 
regenerating reduced glutathione (a critical intracellular antioxidant), a decrease in reduced 
glutathione levels due to lesser availability of NADPH, increases susceptibility to intracellular 
oxidative stress [131] and subsequent ROS-mediated effects. Activation of the polyol pathway 
also results in decreased NADP
+
 and NAD
+
, necessary cofactors in redox reactions throughout 
the body. Decreased levels of these cofactors lead to lesser synthesis of reduced glutathione, 
nitric oxide, myo-inositol, and taurine. Sorbitol may also glycate nitrogen residues of proteins 
like collagen, and the products of these glycations are referred to as AGE [130].  
 
 
1.8.2 Intracellular production of AGE precursors 
 
The intracellular production of AGE precursors is another important mechanism that stresses 
cells. AGE are molecules formed during a non-enzymatic reaction between proteins and sugar 
residues, known as the Maillard reaction [133]. AGE accumulates in the body with aging and its 
accumulation may increase with conditions like diabetes mellitus, renal failure and oxidative 
stress. At the chemical level, a sugar residue reacts with the amino group of a protein to form a 
Schiff-base (Figure 1.12) [133]. This is a rapid and reversible reaction. The Schiff-base then 
forms a more stable Amadori product. Further steps result in the formation of irreversible and 
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stable AGE compounds. The final step of the Maillard reaction is ROS-driven. AGE accelerate 
oxidation and thus favour their own production [134].  
 
 
 
Figure 1.12: A schematic representation of the mechanism involved in the formation of AGE 
compounds. 
 
AGEs are also involved in the development of heart failure in both diabetic and non-diabetic 
patients, i.e. they increase rigidity of heart tissue leading to diastolic and systolic dysfunction 
through coronary artery disease and vascular dysfunction [133]. AGE precursors may damage 
cells in three different ways. Firstly, they modify intracellular proteins including gene 
transcriptional alteration [135, 136]. Secondly, AGE precursors can diffuse out of the cell and 
modify nearby extracellular matrix molecules [137], thus changing signaling between the 
extracellular matrix and the cell thereby causing cellular dysfunction [138]. Lastly, AGE 
precursors are able to diffuse out of the cell and modify circulating proteins such as albumin 
[139]. Modified circulating proteins can bind to and activate AGE receptors, hence causing an 
inflammatory response in the vasculature through the production of cytokines and growth factors 
[139-148]. Through their receptors (RAGEs), AGEs inactivate enzymes by altering their 
structures and functions [149], promoting free radical formation [118, 120], and impair the anti-
proliferative effects of nitric oxide [150, 151]. Moreover, AGEs increase intracellular oxidative 
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stress thereby activating the transcription factor NF-κB and promoting up-regulation of its target 
genes [152] including Bax, Bcl-xL, Bcl-2, caspase-11 and Fas-Ligand [153]. NF-κB also 
enhances production of nitric oxide, thought to contribute to pancreatic islet β-cell damage [153]. 
Such apoptotic gene induction together with increased free radical (superoxide) production 
results in c-Jun NH2-reminal kinase (JNK) and caspase-dependent apoptosis [154]. 
 
 
1.8.3 PKC activation 
 
Another mechanism known to stress hyperglycaemic cells is the PKC pathway. PKC is a family 
of enzymes that control the function of target proteins by phosphorylation of hydroxyl groups of 
serine and threonine amino acid residues. PKC enzymes are activated by upstream signals, e.g. 
diacylglycerol (DAG) [155]. Hyperglycaemia increases the production of DAG that is an 
important co-activator of the classic isoforms of PKC, i.e. β, δ, and α [155-158]. When PKC is 
activated by intracellular hyperglycaemia a variety of effects occur like decreased eNOS 
(endothelial nitric oxide synthase), reduced fibrinolysis, increased NADPH oxidases and 
increased ROS. Thus protective mechanisms are attenuated and detrimental effects increased 
[158]. Upon activation, PKC enzymes are translocated to the sarcolemma by membrane-bound 
receptor for activated protein kinase C proteins (RACK). PKC enzyme activation may remain 
long after the original trigger signal(s). This is achieved by DAG production from 
phosphatidylinositol by a phospholipase. Moreover, FA may also play a role in long-term 
activation of PKC enzymes [155]. 
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1.8.4 Pentose phosphate pathway 
 
Under conditions of oxidative stress, e.g. with hyperglycaemia, there is an increased flux through 
the pentose phosphate pathway (PPP) (Figure 1.13). Glucose 6-phosphate is the entry point of 
the PPP which is converted to ribulose-5-phosphate, a pentose sugar. The pathway has an 
oxidative phase and a non-oxidative phase. Here the conversion of glucose 6-phosphate to 
ribulose-5-phosphate comprises the oxidative phase, while the rest of the pathway is non-
oxidative and involves synthesis of pentose sugars. Though the PPP has not directly been 
implicated in pathogenesis [159], higher lipid biosynthesis due to activation of the pathway may 
play a role in pathogenesis. Under hyperglycaemic conditions, higher NADPH utilization by the 
polyol pathway would increase the activity of PPP for the maintenance of the NADPH:NADP
+
 
ratio. As a result of PPP activation there is increased production of triose phosphate 
intermediates that facilitate the de novo synthesis of DAG. Here the de novo DAG synthesis 
pathway is favoured by a high NADH:NAD
+
 ratio and results in increased DAG levels. 
Subsequently, this leads to increased dihydroxyacetone and glycolytic metabolite accumulation 
thereby causing further damage [160]. 
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Figure 1.13: A schematic representation of the pentose phosphate pathway. 
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1.9 HEXOSAMINE BIOSYNTHETIC PATHWAY 
 
 
Under normal conditions approximately 3% of the total glucose is diverted into the HBP [161]. 
In T2DM there is increased FFA availability and a decreased rate of pyruvate oxidation by PDH 
inhibition, i.e. the Randle effect [116]. Additionally, there is decreased entry of fructose 6-
phosphate into the glycolytic pathway due to citrate-mediated inhibition of PFK. This in turn 
increases fructose 6-phosphate availability to enter the HBP [161].  
 
Figure 1.14: The hexosamine biosynthetic pathway. GlcNAc: N-acetylglucosamine, GFAT: glutamine: 
fructose 6-phosphate amidotransferase, OGT: uridine diphospho-N-acetylglucosamine: polypeptide β-N-
acetylglucosaminyltransferase. 
 
 
52 
 
 
When fructose 6-phosphate enters the HBP the enzyme glutamine:fructose 6-phosphate 
amidotransferase (GFAT) converts it to glucosamine-6 phosphate (Figure 1.14). Through a series 
of subsequent reactions, glucosamine 6-phosphate is converted into uridine diphosphate N-acetyl 
glucosamine (UDP-GlcNAc), the end-product of the HBP. Subsequently, N-acetyl glucosamine 
is transferred in an O-linkage to specific serine and threonine residues of proteins and 
transcription factors, similar to the more familiar phosphorylation process [162]. In fact, the O-
GlcNAcylation sites are identical or adjacent to known phosphorylation sites suggesting a 
regulatory function. The O-linkage to target proteins is carried out by O-GlcNAc transferase 
(OGT) [162]. Thus the HBP is an important regulatory pathway that functions by post-
translationally modifying target proteins and altering their functions (Table 1.1) [162]. 
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Protein Metabolic 
Relevance 
Species Tissue Residues O-
GlcNAcylat
ed 
Effect of O-
GlcNAc 
Ref. No. 
Sp1 Transcription factor. 
Regulates expression 
of multiple genes and 
proteins including 
SERCA2a, PAI-1, 
etc. 
Rat Neonatal rat 
ventricular 
myocytes 
612-702 (Ser
612
, 
Thr
640
, Ser
641
, 
Ser
698
 and 
Ser
702)
 
Decreased 
transcriptional 
activity 
[163, 164] 
p53 Regulates stress 
responses during 
glucose starvation 
Rat, 
Human 
Adult rat 
ventricular 
myocytes, 
HEK-293 cells 
141-156 
(Ser
149
) 
Increased activity [165, 166] 
NF-κβ Regulates promoter 
activation 
Rat Mesangial cells 322-352 
(Thr
322
, Thr
352
) 
Increased activity [167, 168] 
IRS-1 Regulates insulin 
signaling 
Rat, 
Human 
Skeletal 
muscles, HEK-
293 cells 
1027-1073 
(Ser
1036
) 
Decreased activity [169, 170] 
PI3K Mediates various 
signaling pathways 
Human Human 
coronary artery 
endothelial 
cells 
 
Decreased activity 
and less 
phosphorylation 
[171] 
GLUT-4 Mediates glucose 
transport 
Rat Primary 
adipocytes 
486-498, 469-
472 
Decreased 
translocation 
[172, 173] 
Akt2 Role in insulin 
signaling 
Rat Primary 
adipocytes 
 
Decreased insulin 
response 
[172] 
Glycogen 
synthase 
Mediates glycogen 
synthesis 
Rat 3T3-L1 
adipocytes 
(Ser
7
, Ser
640
) Decreased 
activation 
[174] 
eNOS Regulates vascular 
function 
Bovine 
heart 
Bovine aortic 
endothelial 
cells 
(Ser
1177) 
Decreased activity [175] 
c-Myc Transcription factor, 
oncogene 
Human Sf9 insect cells 53-65 
(Thr
58
) 
Affects 
transcription 
[176] 
 
Table 1.1: Some targets of O-GlcNAcylation and its effect on the protein. 
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1.9.1 HBP as a “fuel sensor” 
 
The HBP acts as a “fuel sensor” that senses/regulates the rates of glucose and FFA flux into the 
cell [177]. Studies also show that HBP not only “senses” nutrients at the cellular level but also at 
whole body level by regulating leptin expression [177]. Nutrient availability e.g. glucose, FA, 
amino acids and nucleotides, modulate intracellular UDP-GlcNAc levels. For example, glucose 
levels regulate O-glycosylation on various proteins including OGT [178]. OGT is known to have 
altered specificity at different levels of O-GlcNAc, thereby suggesting a role as nutrient sensor 
[179]. The HBP also acts as a sensor of lipids e.g. hexosamines act as sensors to divert excess 
calories to be stored as fat [180].  
Under a highly fed state when O-GlcNAc levels are high, it may have a negative feedback effect, 
resulting in decreased glucose uptake via the PI3/Akt/PKB or AMPK pathways [181, 182]. O-
GlcNAc can mediate such effects by direct protein modification or indirectly by modification of 
transcription factors and expression levels, or by protein degradation [178]. There is considerable 
data showing that GFAT over expression in liver results in increased fat export to adipocytes 
even under lower plasma glucose levels [183]. Moreover, it also leads to increased fat accretion 
and hyperlipidemia in fat tissues and autoregulatory decrease in insulin-stimulated glucose 
uptake in muscle cells [180]. These data obtained from transgenic animal models correlate with 
human studies [184]. OGT homologs also exist in plants and yeast. When the OGT homolog in 
plants (SPINDLY) is deleted this results in tall and skinny plants which do not store starch in 
their roots [185]. Together these data show that the HBP is able to sense nutrient levels and 
direct excess nutrient intake into storage depots for later use [186]. 
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However, with the onset of T2DM there is increased HBP flux [187]. Skeletal muscle GFAT 
activity is markedly increased in T2DM patients [188]. Similar studies also show that obese mice 
with elevated blood glucose and insulin levels exhibit higher GFAT activity [189]. In agreement, 
increased UDP-GlcNAc levels were found in diabetic rats [163]. In vivo insulin resistance was 
associated with impaired translocation of GLUT4 to the sarcolemma [190] proposed to occur as 
a result of HBP activation. Moreover, with hyperglycaemia there is also oxidative and 
endoplasmic reticulum stress that could also lead to insulin resistance [191]. Although this is a 
fairly recent mechanism recognized to play a role in pathogenesis of diabetic complications, it 
plays a role both in hyperglycaemia-induced abnormalities [192] and in hyperglycaemia-induced 
cardiomyocyte dysfunction [163].  
 
1.10 DIABETES AND APOPTOSIS 
 
Several studies have shown that high glucose levels cause apoptosis [193, 194] and 
hyperglycaemia-mediated ROS production and subsequent mitochondrial cytochrome-c release 
and caspase activation are strongly implicated in this process [195]. Before discussing details of 
the link between diabetes and apoptosis, the focus will now shift on some of the basics of 
apoptosis. 
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1.10.1 Apoptosis 
 
Apoptosis (programmed cell death) is a highly regulated process to eliminate dysfunctional cells 
in the body. During this process the genome breaks, the cell shrinks and disintegrates into 
smaller apoptotic bodies that are then phagocytosed by macrophages before the cell contents leak 
into the environment [196]. This is unlike necrosis where the cell swells and bursts, releasing its 
contents into the environment and causing an inflammatory response (Table 1.2).  
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Table 1.2: Differences between apoptosis and necrosis 
Apoptosis can be triggered in 2 ways i.e. (1) extrinsic and (2) intrinsic pathways [196]. Extrinsic 
apoptosis is initiated by transmembrane death receptors such as Fas, while the intrinsic pathway 
is triggered by signals released from organelles, e.g. mitochondria [196].  
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The extrinsic pathway is triggered by signal molecules (ligands) that are released by other cells. 
For example, Fas ligand (FasL) binds to transmembrane death receptors of the target cell and 
induce apoptosis [197]. When ligands bind to death receptors on target cells, it triggers various 
receptors to aggregate on the cell surface. These aggregated receptors recruit an adaptor protein 
known as the death domain (DD) protein which in turn recruits caspase-8 to the complex making 
it a death-inducing signal complex (DISC) (Figure 1.15). Caspase-8 (an initiator protein) 
subsequently activates caspase-3, an effector protein, thereby initiating cell death [197]. 
 
Figure 1.15: A schematic representation of extrinsic apoptotic pathway. DD: Death domain; DISC: 
Death-inducing signal complex; DED: Death effector domain; FLIP: FADD-like IL-1 -converting enzyme 
(FLICE)-inhibitory protein. 
As the name suggests, the intrinsic pathway is triggered by intracellular stress, specifically 
mitochondrial stress [198]. In response to a stress signal, pro-apoptotic proteins in the cytoplasm 
e.g. Bax bind to the outer membrane of mitochondria and trigger the release of mitochondrial 
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contents and cytochrome-c (Figure 1.16) [198]. Following this, cytochrome-c forms a complex 
with ATP and Apaf-1 in the cytoplasm. This activates caspase-9 that joins the complex and 
forms an apoptosome that activates caspase-3 to initiate cellular degradation [198].  
 
Figure 1.16: A schematic representation of intrinsic apoptotic pathway. 
In the context of this thesis, disruption of the mitochondrial membrane plays a key role in 
mediating the intrinsic apoptotic pathway. Activation of pro-apoptotic proteins BAD and Bax 
and inactivation of anti-apoptotic protein Bcl-2 are involved in this process [199]. Here 
phosphorylated BAD can dimerize with the 14.3.3 protein and prevent the usual apoptotic 
cascade. When BAD is dephosphorylated it carries out its pro-apoptotic function by dimerizing 
with Bcl-2 (Figure 1.17) [199]. Bcl-2 is inactivated upon dimerization and is unable to perform 
its anti-apoptotic function, i.e. binding Bax to prevent it from disrupting the mitochondrial 
membrane. Hence Bax is now able form homodimers, insert into the mitochondrial membrane 
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and subsequently cause membrane disruption and release of mitochondrial contents and 
cytochrome-c, thereby leading to intrinsic cell death [200]. 
 
Figure 1.17: Diagram representing the mechanism behind mitochondrial membrane disruption. 
For this thesis, we focused on ways to measure the intrinsic mode of apoptosis triggered by 
hyperglycaemia, as diabetes-mediated apoptosis largely occurs due to intracellular signals 
deriving from organelles like the mitochondria. 
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1.10.2 Hyperglycaemia-mediated apoptosis 
 
With diabetes there is increased cellular stress which leads to altered fuel intake and increased 
ROS production and glucotoxicity as explained earlier. Apoptosis is an important contributor to 
heart failure in patients with diabetes [201]. An early response of myocardial cells to 
hyperglycaemia includes metabolic remodeling, sub cellular defects and abnormal expression of 
genes, all of which may eventually contribute to cardiac cell death [193].  In agreement, previous 
studies show that hyperglycaemia mediates apoptosis [193, 194].  For example, human umbilical 
vein endothelial cells exposed to 30 mM glucose for 72 hours exhibited increased apoptosis 
[202].  Moreover, aortic endothelial cells exposed to 30 mM glucose culturing conditions 
displayed greater glucose oxidation, increased superoxide production [24] and DNA damage.  
PARP is subsequently activated [129] resulting in apoptosis [203].   hyperglycaemia may also 
act as a stress signal, resulting in cytochrome-c release, the activation of caspase-3 [193] and 
apoptosis. Moreover, apoptotic cell death in response to hyperglycaemia may be dose-dependent 
indicating a greater degree of apoptosis with higher glucose levels [193]. As mentioned in 
Section 1.8, hyperglycaemia-induced apoptosis may be mediated by various pathways including 
the pentose phosphate pathway, polyol pathway, PKC activation and AGEs. Furthermore, studies 
show that the HBP also plays a role in apoptosis [204] - this forms the basis of my research 
project.  
Although the HBP is a contributor to cell death during diabetes [204], the exact mechanisms 
underlying this process in the heart are unclear. Interestingly, studies have shown that O-
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GlcNAcylation of certain proteins can lead to increased apoptosis. For example, 
hyperglycaemia-induced HBP flux leads to greater O-GlcNAcylation of p53 resulting in 
increased angiotensin synthesis and apoptosis [165]. Others have also reported that decreased 
levels of BAD, a pro-apoptotic Bcl-2 homolog, may be implicated in HBP-mediated pancreatic 
β–cell death [205].  However, despite these advances the underlying mechanisms mediating 
hyperglycaemia-mediated myocardial cell death are still poorly defined. 
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1.11 HYPOTHESIS 
 
Within the diabetic setting there is increased onset of CVD [8-10] associated with elevated 
intracellular oxidative stress [118-120]. This leads to increased HBP flux and “glucose toxicity” 
[188] proposed to occur via increased O-GlcNAc modification of target proteins [129]. Since 
elevated intracellular oxidative stress and greater HBP flux are robustly associated with the 
diabetic phenotype, we hypothesized that higher oxidative stress under hyperglycaemic 
conditions causes greater O-GlcNAcylation of BAD, thereby increasing myocardial 
apoptosis.  
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1.12 AIMS 
 
1. Establish an in vitro model of hyperglycaemia-induced apoptosis 
2. Evaluate oxidative stress in response to hyperglycaemia 
3. Assess the role of the HBP in hyperglycaemia-mediated apoptosis 
4. Determine the degree of BAD O-GlcNAcylation with hyperglycaemia                                                
5. Test our hypothesis in hearts of a rat model of hyperglycaemia/insulin resistance 
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Our initial approach was to establish a hyperglycemic cell model. Subsequently, we evaluated 
the role of the HBP in mediating cell death under these conditions .Finally, we tested our 
hypothesis by employing an in vivo rat model of insulin resistance. 
 
2.1 CELL CULTURE: In vitro model 
 
H9c2 rat cardiomyoblasts were used for experiments as they are a precursor cell line to 
cardiomyocytes (Sigma-Aldrich, Steinheim, Germany) [1]. Cells were cultured at 37˚C (5% 
CO2, 95% air) in T75 culture flasks using Dulbecco Modified Eagle‟s Medium (DMEM) (Sigma-
Aldrich, Steinheim, Germany) containing 10% fetal bovine serum (Invitrogen, Carlsbad, CA). 
The final glucose concentration in DMEM was 5.5 mmol/L. Cells were sub cultured when the 
flasks were ~ 80% confluent. This usually took between three and four days. 
 
2.1.1 Pharmacologic treatment to modulate flux through the HBP 
 
After seeding, cells were allowed to plate where after various treatments were employed to test 
our hypothesis. On the first day, cells were split into three groups. One group was given a low 
glucose DMEM (5.5 mM), and the second and third groups treated with high glucose DMEM 
containing 22 and 33 mM glucose, respectively [2-4]. [Note: The choice of 22 and 33 mM 
glucose is based on previous studies which employed the same high glucose concentrations [2-
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4]. The rationale is that since H9c2s are usually maintained in a 25 mM glucose-DMEM when 
not used in glucose-dependent experiments,  we chose 33 mM glucose as a ‘’hyperglycaemic’’ 
dose.] To simulate chronic hyperglycaemia, the high glucose treatment was given for 5 days with 
treatment initiated on Day 1. On the second day, various pharmacological agents were 
introduced that either activate or inhibit the HBP. Here we used 40 µM DON (6-diazo 5-oxo-L-
norleucine) (Sigma-Aldrich, St.Louis, MO) [5] an inhibitor of GFAT, the rate limiting enzyme of 
the HBP; 50 µM PUGNAc (O-(2-acetamido-2-deoxy-D-glucopyranosylidene)amino N-phenyl 
carbamate) (Sigma-Aldrich, St.Louis, MO) [6] an inhibitor of O-GlcNAcase; and 250 µM α-
OHCA (α hydroxyl cinnamic acid) (Sigma-Aldrich, St.Louis, MO) [7] an anti-oxidant. A 
combination of PUGNAc and α-OHCA was also given to assess whether an antioxidant would 
blunt PUGNAc-mediated effects. No pharmacological agents were added to low and high 
glucose controls. We routinely administered pharmacological agents for three days (Day two to 
Day four) with fresh media where after cells were analysed to assess the degree of apoptosis on 
Day 5 (Figure 2.1). We employed various methods to evaluate apoptosis, i.e. Hoechst nuclear 
staining, caspase activity assay and Annexin-V staining (R&D Systems, Germany). We also 
assessed ROS levels by H2DCFDA staining.  
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                                                       H9c2 myoblasts 
 
                                                      Cultured in DMEM 
 
Day 1:     Low glucose treatment           High glucose treatment 
                           (5.5 mM)                        (22 mM) & (33 mM) 
               
 
 
Day 2:                                 Drug treatment         
                                   (Maintained until Day 4)                    
 
Day 5:                 Evaluate apoptosis by various methods 
 
Figure 2.1:  A schematic representation of experimental plan. 
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2.1.2 Transfections to enhance flux through the HBP 
 
Transfection is a procedure where exogenous DNA (encoding candidate protein) is transferred 
into cells.  This is useful to investigate effects of brought about by overexpression of the 
candidate protein in a cell-based system.  Here the transfected plasmid DNA incorporates into 
the host DNA and the candidate protein is expressed. 
  
For our experiments, we increased HBP flux by employing a pcDNA3-GFAT plasmid [8] 
construct to over express GFAT, the rate-limiting enzyme of this pathway.  We also employed a 
dominant negative GFAT construct, pcDNA3-GFAT/676 [9] (in which 676 lysine is mutated to 
alanine) that should inhibit HBP flux. Both these constructs were kindly donated to us by Dr. 
Cora Weigert based at the University of Tübingen in Germany.  
 
H9c2 myoblasts were trypsinized on Day 1 and counted in a haemocytometer (LASEC, South 
Africa). Approximately 35,000 cells were then seeded in each well of a 12-well plate with 1 ml 
DMEM and allowed to plate for 24 hrs.  The transfection was performed on Day two (Figure 
2.2).  Here, we first made up 0.25 µg of pcDNA3-GFAT in DMEM without serum.  We next 
made up a solution of the transfection reagent - Fugene 6 (Roche, Penzberg, Germany) - in 
DMEM without serum.    We employed a 2:1 ratio for Fugene 6: plasmid DNA as is routinely 
done in our laboratory for similar type of experiments.  The two solutions were mixed and 
incubated at room temperature for 15 minutes. Just before the transfection was performed, we 
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added 0.9 ml fresh media and 100 µL of the Fugene-DNA cocktail to the cells. The plates were 
gently rocked to evenly spread the cocktail and thereafter incubated at 37°C for 24 hrs. On Day 
three, the media was removed and fresh medium was given to the cells.  On Day four, cell 
lysates were harvested using RIPA buffer and stored at -80°C until further use. The protein 
lysate was used for immunoprecipitation and Western blotting analysis. Two independent 
experiments were performed with each condition in triplicates. 
 
 
 
 
 
 
 
 
 
Figure 2.2: A schematic representation of the transfection procedure 
 
 
Day 1:  Seed 35,000 H9c2 myoblasts in 12-well plates 
Day 2:  Transfection performed 
Day 3: Media changed 
Day 4: Cell protein lysate harvested using RIPA buffer 
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2.2 IN VIVO RAT MODEL OF INSULIN RESISTANCE 
 
Previously collected heart tissues provided by Dr. Saartjie Roux (Department of Biochemistry 
and Microbiology at the Nelson Mandela Metropolitan University, South Africa). Here, three-
week-old male Wistar rats were fed high fat diet (Harlan Teklad, TD.95217, Wisconsin, USA) 
for 86 days and compared to matched controls (Harlan Teklad, TD.06683, Wisconsin, USA).  
Rats fed high fat diet displayed a moderate but significant increase in body weight (7.3 ± 1.3%, 
p<0.05 vs. controls). These rats became insulin resistant since muscle glucose uptake was 
significantly lower in high fat versus the control group (Insulin resistance was measured by 
calculating HOMA-IR using the formula HOMA-IR = fasting plasma immunoreactive insulin 
(IRI; µU/l) × fasting plasma glucose (FPG; mmol/l)/22·5. The high fat diet group showed a 3-5 
fold increase in HOMA-IR values compared to the control diet group). Moreover, fasting plasma 
glucose levels were increased by 23.5 ± 7% in these animals (p<0.05 vs. matched controls) 
suggesting that they were hyperglycaemic. 
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2.3 EVALUATION OF APOPTOSIS 
 
2.3.1 Hoechst nuclear staining 
 
During apoptosis nuclei condense and fragment. With Hoechst staining, the nuclei of cells are 
stained and this can be used as an indicator of condensed/fragmented nuclei undergoing 
apoptosis [2]. 
 
H9c2 myoblasts were trypsinized and counted in a haemocytometer (LASEC, South Africa). 
Approximately 200,000 cells were then seeded in a 35 mm petridish with a cover slip and 2 ml 
of DMEM where after various treatments were administered as explained in Section 2.1.1. To 
exclude the possibility of cell death due to osmotic effects, we performed similar experiments as 
described but using 22 mM and 33 mM mannitol vs 5.5 mM glucose controls. 
 
Cover slips were removed after the completion of experiments and placed over glass slides. 
Cover slips were then washed with 500 µL of ice cold PBS (phosphate buffer solution), treated 
with 1 ml of fixative (1:1 acetone : methanol) and thereafter incubated at 4°C for 10 minutes. 
The fixative was then removed and cover slips again washed with 500 µL ice cold PBS. 100 µL 
of Hoechst stain (4´-6´ diamidino-2-phenylindole - DAPI) (Sigma-Aldrich, Steinheim, Germany) 
(1:200 dilution of stock in PBS) was added onto cover slips an incubated in the dark for 20 
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minutes. Since Hoechst is a fluorescence stain, any external light might affect the signal and 
hence incubations were performed in the dark. The stain was then washed off twice with 500 µL 
PBS and the cover slips thereafter mounted on permanent slides that were then viewed under a 
Nikon E-400 fluorescence microscope (Nikon microscopes, Kobe, Japan). Images were acquired 
using a Nikon DM X 1200 colour digital camera (Nikon microscopes, Kobe, Japan) using ACT-I 
software (Nikon microscopes, Kobe, Japan) to process the images. Three independent 
experiments were conducted and four images of each condition were acquired resulting in 12 
images being captured per experiment. For each image the number of condensed/fragmented 
nuclei was counted and expressed as a percentage of total number of nuclei counted. In this 
manner the percentage apoptosis was determined for each experimental condition. 
 
2.3.2 Caspase activity assay 
 
The caspase activity assay was used to measure the active caspase activity in cells under 
hyperglycaemic conditions ± various HBP drug treatments. The degree of caspase activation 
was taken as a marker of apoptosis. The Caspase-Glo® 3/7 assay kit (Promega, Madison, WI) 
contains a lysate which lyses cells. A luminogenic caspase 3/7 substrate is added to the lysed 
cells. Activated caspases cleave the luminogenic substrate, releasing amino-luciferin (Figure 
2.3). The latter is a substrate for luciferase resulting in the production of light that is measured 
using a Glomax luminometer (Sigma-Aldrich, St.Louis, MO). The degree of luminescence is 
therefore a measure of caspase activity and apoptosis. 
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Figure 2.3:  A schematic representation of the Caspase-Glo
®
 3/7 assay 
 
H9c2 myoblasts were trypinized, counted in a haemocytometer (LASEC, South Africa) and ~ 
10,000 cells seeded per well of a 96-well plate (Greiner, Kremsmünster, Austria). Cells were 
seeded with 500 µL DMEM. Negative controls were also included in these experiments and here 
the cells were treated with the vehicle (90% saline) only. We used 90% saline to dissolve the 
drugs and hence saline acted as a vehicle. We also included a blank reaction, i.e. vehicle and 
DMEM with no cells. The experiments were performed 6 times (n=6). 
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     Add luminogenic 
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Following caspase cleavage 
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for luciferase, releasing light 
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The caspase assay kit was reconstituted as detailed in the manufacturer‟s instruction booklet. 
Here the DMEM from cells was removed and 100 µL of the reconstituted assay reagent was 
added onto each well and mixed gently. Cells were thereafter incubated at room temperature for 
~ two hours. Care is taken to incubate the cells with the reagent in dark so that the natural light 
does not interfere with the luminescence of the experiment. The luminescence of the samples 
was measured in a luminometer. For this purpose, special white walled 96-well luminometer 
plates (Amersham, Buckinghamshire, UK) were used. The reagent-treated experiments from the 
normal 96-well plate were transferred into the white-walled luminometer plate that was then 
placed in a luminometer and readings taken for each well. The luminescence of each well 
corresponds to the caspase activity in that well.  
 
2.3.3 Annexin-V staining 
 
During the early stage of apoptosis, the phospholipid asymmetry of the cell membrane is 
disrupted exposing phosphatidyl serine residues on its outer leaflet. This is an important event 
for macrophage recognition of cells undergoing apoptosis. Annexin-V binds to the exposed 
phosphatidyl serine residues, thereby tagging apoptotic cells. Annexin-V is an anti-coagulant 
protein that preferentially binds negatively charged phospholipids. We employed Annexin-V 
conjugated with FITC (R&D Systems, Germany)[10] allowing us to measure fluorescence when 
viewed using a fluorescence microscope. 
 
91 
 
For the purpose of fluorescence microscopy, Nunc
™
 chambered cover glass (Nalge Nunc, 
Rochester, NY) were used. As before, H9c2 myoblasts were trypsinized, counted and ~ 15,000 
cells seeded per well in an 8-well Nunc
™
 chambered cover glass. We seeded the cells with 500 
µL of DMEM. Subsequently, various pharmacologic treatments were administered as described 
in Section 2.1.1. of the thesis. 
 
DMEM in the wells were removed and the cells were washed with 300 µL of warm 1 X PBS. 
The Annexin-V incubation buffer was prepared as detailed in the manufacturer‟s instruction 
booklet, i.e. using 10 µL of 10 X binding buffer, 10 µL propidium iodide, 0.5 µL Annexin V-
FITC and 79.5 µL distilled water. Thus a total of 100 µL of incubation buffer was prepared per 
sample. Propidium iodide was included in the incubation buffer to differentiate between 
apoptotic and necrotic cell death as propidium iodide can stain the nuclei of necrotic cells with 
non-intact cell membranes. 100 µL of the incubation buffer was added to each well. This was 
incubated in the dark at room temperature for 15 minutes. As Annexin V-FITC is a fluorescence 
staining procedure, any external light affects the signal causing background and hence the 
staining needs to be performed in the dark.  
 
After incubation, cells were washed twice with 300 µL of 1 X binding buffer provided with the 
kit. Thereafter, 100 µL of warm PBS was added and cells viewed under an Olympus CellˆR 
fluorescence 1 X 81 inverted microscope (Olympus Biosystems, Germany) using an F-view II 
camera (Olympus Biosystems, Germany) for image acquisition and CellˆR software, Olympus 
Biosystems, Germany) for processing images. Warm PBS was used since the cells being viewed 
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are still alive and therefore this procedure should minimize stress on these cells. The temperature 
of the microscope system was maintained at 37°C for live cell imaging using a Solent Scientific 
microscope incubator chamber (Solent Scientific, UK). The green intensity of all cells expressing 
Annexin-V signal were measured, providing a numerical value for the degree of apoptosis. Four 
independent experiments were conducted and three images acquired per well. Cells displaying 
propidium iodide staining were considered necrotic and were excluded from our analysis.  
 
2.3.4 Western blot analysis 
 
Western blotting analysis was used to quantify peptide levels of O-GlcNAcylated and apoptotic 
proteins. Protein extracts from the in vitro and in vivo experiments are resolved using SDS-
polyacrylamide gel electrophoresis (PAGE), probed for candidate proteins and quantified to 
estimate protein expression. 
 
2.3.4.1 Isolation of cellular protein extracts 
  
H9c2 myoblasts were trypsinized, counted and ~ 300,000 cells seeded in 5 ml DMEM in T-25 
flasks (Greiner, Kremsmünster, Austria). Subsequently, various pharmacologic treatments were 
administered (described in Section 2.1.1). Following treatment protein was harvested by 
scrapping cells off the flask using freshly prepared modified RIPA buffer (refer Appendix 1.1). 
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The collected lysate was then sonicated and centrifuged (ALC PK121R Multispeed refrigerated 
centrifuge) for 10 minutes at 4300 x g at 4°C and subsequently the supernatants were stored at -
80°C. Total protein was quantified by the Bradford method (refer Appendix 2).  
 
2.3.4.2 Isolation of heart tissue protein extracts 
 
To extract proteins from the heart tissues, small pieces of the heart tissues were placed inside 
homogenizing tubes containing freshly prepared modified RIPA (Appendix 1.1) and 
homogenized for about a minute, and thereafter left on ice for an hour until foam subsided. This 
was subsequently centrifuged at 4300 x g set for 10 minutes at 4°C. The supernatant was 
collected and re-centrifuged as before. The supernatant was collected and stored at -80°C until 
further use. Total protein in the samples was quantified using Bradford method (Appendix 2). 
 
2.3.4.3 SDS-PAGE 
 
Western Blot protein samples (cellular and tissue extracts) were prepared by adding 50 µg of 
protein to an equal amount of sample buffer (3x sample buffer: 33.3 ml stacking buffer, 8.8 g 
SDS, 20 g glycerol and bromophenol blue in 75 ml distilled water; 850 µL 3x sample buffer + 
150 µL mercaptoethanol was used as the working sample buffer solution). Samples were 
subsequently boiled for 5 minutes before being loaded for PAGE. The samples were 
electrophoresed on a 10% SDS-PAGE gel (with a 4% stacking gel) at 200 V for one hour. 10 µL 
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of protein marker (Bio-RAD Plus Protein
™
 Dual Colour Standards, CA) was included (Lane 1), 
with experimental samples loaded in the remaining lanes. After one hour, proteins from the gel 
were transferred to a PVDF membrane (Immobilon-P, Millipore Corporation, MA) by semi-dry 
electrotransfer (refer Appendix 3). This membrane was used to probe for caspase-3, BAD and 
cytochrome-c (Cell Signaling, MA) in order to assess the degree of apoptosis (refer Appendix 4 
for protein detection methodology). 
 
Protein expression was determined by densitometry. Here the developed film was scanned using 
an HP Scanjet 3500c scanner (Hewlett packard, Palo Alto, CA) and densitometry was performed 
using Un-Scan-It Gel version 5.1 (Silk software, Orem, UT). The densitometry value of the 
investigated proteins was normalised to the densitometry value of the corresponding β-actin. The 
normalized densitometric value was used for statistical analysis when evaluating relative 
differences in protein expression.  
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2.4 ASSESSMENT OF OXIDATIVE STRESS 
 
2.4.1 DCF-DA staining 
 
Derivatives of reduced fluorescein and calcein act as cell-permeable indicators for ROS. 
Chemically reduced and acetylated forms of 2',7'-dichlorofluorescein (DCF)  are non-
fluorescent until the acetate groups are removed by intracellular esterases. Esterase cleavage of 
the lipophilic blocking groups yields a charged form of the dye that is much better retained by 
cells than its parent compound. This can fluoresce when excited and hence higher fluorescence 
indicates greater ROS levels. Oxidation of probes can be detected by monitoring increased 
fluorescence. The latter may be assessed by a variety of methods, e.g. flow cytometry or 
fluorescence microscopy [2, 11]. With hyperglycaemia there is increased ROS production [12-
15] that may result in detrimental effects. We employed this ROS staining procedure to measure 
ROS levels in response to hyperglycaemia ± HBP pharmacologic modulators. 
 
For the purpose of fluorescence microscopy, Nunc
™
 chambered cover glass (Nalge Nunc, 
Rochester, NY) were employed. As before, H9c2 myoblasts were trypsinized, counted and ~ 
15,000 cells seeded per well in an 8-well Nunc™ chambered cover glass. We seeded the cells 
with 500 µL DMEM. Subsequently, various pharmacologic treatments were administered as 
described in Section 2.1.1. 
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DMEM in wells were removed and H9c2 myoblasts were washed with 300 µL of warm 1 X 
PBS. We originally prepared a 1 M H2DCFDA stock by dissolving it in 210 µL distilled water. 
Several aliquots of 10 mM stocks were thereafter made by diluting 10 µL of 1 M stock into 990 
µL of DMSO. The working solution was prepared by a 1:200 dilution of the 10 mM dye stocks 
in PBS. 100 µL of the working H2DCFDA solution was added per well and incubated in the 
dark for 10 minutes at 37°C. Since the cleaved DCF is a fluorescent substrate, any external light 
affects the signal causing background and hence this procedure needs to be performed in the 
dark. The dye was then removed and 100 µL PBS added to cells. Cells were thereafter viewed 
using a Olympus CellˆR fluorescence 1 X 81 inverted microscope (Olympus Biosystems, 
Germany) using an F-view II camera (Olympus Biosystems, Germany) for image acquisition and 
CellˆR software (Olympus Biosystems, Germany) for processing images. The temperature of the 
microscope system was maintained at 37°C for live cell imaging using a Solent Scientific 
microscope incubator chamber (Solent Scientific, UK). The green intensity of all cells expressing 
DCF signal was measured, generating a numerical value corresponding to ROS levels and 
oxidative stress. Four independent experiments were conducted and 3 images per experiment 
acquired. Thus an n=12 was generated for each experiment.  
 
2.4.2 ROS measurement by flow cytometry 
 
We also assessed ROS levels by flow cytometry in order to obtain population data (versus single 
cell data) [16]. Flow cytometry simultaneously measures and analyzes multiple physical 
characteristics of single particles, usually cells, as they flow in a fluid stream through a beam of 
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light. The properties measured include a particle’s relative size, granularity or internal 
complexity, and fluorescence intensity. These characteristics are determined using an optical-to-
electronic coupling system that records how the cell or particle scatters incident laser light and 
emits fluorescence. 
 
H9c2 myoblasts were trypsinized, counted and ~ 300,000 cells seeded in 5 ml DMEM in T-25 
flasks (Greiner, Kremsmünster, Austria). Subsequently, various pharmacologic treatments were 
administered to test our hypothesis (described in Section 2.1.1). 
 
DMEM from flasks was removed and H9c2 myoblasts were washed with 2 ml of warm PBS. 
Warm PBS was used since the cells being viewed are still alive and the slightest stress may 
affect ROS levels. Cells were then trypsinized with 2 ml of Trypsin-EDTA solution (Sigma-
Aldrich, St.Louis, MO) and pelleted by centrifuging in a Digicen 20-R Ortoalresa centrifuge 
(United Scientific, South Africa) for 2 minutes at 1358 x g at 37˚C. The cell pellet was then 
treated with 1 ml of working solution of the dye. We originally prepared a 1 M H2DCFDA stock 
by dissolving it in 210 µL distilled water. Several aliquots of 10 mM stocks were thereafter made 
by diluting 10 µL of 1 M stock into 990 µL of DMSO. The working solution was prepared by a 
1:200 dilution of the 10 mM dye stocks in PBS. The dye-treated cell pellet was suspended 
without clumps and incubated in the dark for 20 minutes at 37°C. As the cleaved DCF is a 
fluorescent substrate, any external light affects the signal causing background and hence the 
staining needs to be performed in darkness. The cells were then run through FACS Aria flow 
cytometer (Becton-Dickinson, CA) and population data obtained.  
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Cells not treated with ROS dye served as negative controls, and stained cells treated with 100 µL 
hydrogen peroxide (30% w/v hydrogen peroxide) incubated for 10 minutes served as positive 
controls. Three independent experiments were conducted for each condition investigated. The 
geometric mean of the fluorescence of a cell population represented the numerical value of the 
experiment which was used for analysis.  
 
2.5 ASSESSMENT OF HBP FLUX 
 
2.5.1 Measurement of O-GlcNAc by fluorescence staining 
 
Fluorescence microscopy can be used to visualize and measure proteins or similar groups on 
proteins by tagging them with a specific primary antibody which can then be picked up by its 
specific secondary antibody which is fluorescent. This process is known as 
immunohistochemistry. When O-GlcNAc is bound to its antibody and in turn to a fluorescent 
secondary antibody, it can fluoresce and this fluorescence intensity can be used as a measure of 
the amount of O-GlcNAc present within the system. The greater the fluorescence intensity, the 
more protein present.  
 
For the purpose of fluorescence microscopy, Nunc™ chambered cover glass (Nalge Nunc, 
Rochester, NY) were employed. As before, H9c2 myoblasts were trypsinized, counted and ~ 
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15,000 cells seeded per well in an 8-well Nunc™ chambered cover glass. We seeded the cells 
with 500 µL of DMEM. Subsequently, various pharmacologic treatments were administered as 
described in Section 2.1.1. 
 
DMEM in wells were removed and H9c2 myoblasts were washed with 300 µL of cold PBS. 
Cells were then fixed in acetone:methanol (1:1) fixative for 10 minutes. Thereafter they were 
incubated in 5% donkey serum for 20 minutes to block non-specific binding sites. The cells were 
then incubated in 1:50 O-GlcNAc primary antibody overnight at 4˚C. They were then thoroughly 
washed with cold PBS four to five times and thereafter treated with the secondary Texas Red 
antibody (1:200 dilution) for 30 minutes in the dark. Since the secondary Texas Red antibody is 
fluorescent, any external light affects the signal causing background and hence this procedure 
needs to be performed in the dark. Subsequently, cells were thoroughly washed using cold PBS 4 
to 5 times and henceforth maintain under a thin film of cold PBS for imaging. Cells were 
thereafter viewed using a Olympus CellˆR fluorescence 1 X 81 inverted microscope (Olympus 
Biosystems, Germany) using an F-view II camera (Olympus Biosystems, Germany) for image 
acquisition and CellˆR software (Olympus Biosystems, Germany) for processing images. The red 
intensity of all cells expressing O-GlcNAc signal were measured, generating a numerical value 
corresponding to O-GlcNAc levels and HBP flux. Three independent experiments were 
conducted and 4 images per experiment acquired. 
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2.5.2 Assessment of O-GlcNAcylation by Western blot analysis 
 
O-GlcNAc modification of proteins via the HBP pathway is a relatively common phenomenon. 
When protein extracts are probed for O-GlcNAc, differences in the degree of O-GlcNAcylation 
may be observed which would help us determine the effects of various treatments on O-GlcNAc 
modifications. 
 
2.5.2.1 Isolation of cellular protein extracts 
 
H9c2 myoblasts were trypsinized, counted and ~ 300,000 cells seeded in 5 ml DMEM in T-25 
flasks (Greiner, Kremsmünster, Austria). Subsequently, various pharmacologic treatments were 
administered (described in Section 2.1.1). Following treatment, protein was harvested by 
scrapping cells off the flask using freshly prepared modified RIPA buffer (refer Appendix 1.1). 
The collected lysate was then sonicated and centrifuged (ALC PK121R Multispeed refrigerated 
centrifuge) for 10 minutes at 4300 x g at 4°C and subsequently the supernatants were stored at -
80°C. Total protein was quantified by the Bradford method (refer Appendix 2).  
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2.5.2.2 Isolation of heart tissue protein extracts 
 
To extract proteins from the heart tissues, small pieces were placed inside homogenizing tubes 
containing freshly prepared modified RIPA (Appendix 1.1) and homogenized for about a minute, 
allowed to stand on ice for an hour until foam subsided. This was subsequently centrifuged at 
4300 x g for 10 minutes at 4°C. The supernatant was collected and re-centrifuged as before. The 
supernatant was thereafter stored at -80°C. Total protein in the samples was quantified using 
Bradford method (Appendix 2). 
 
2.5.2.3 SDS-PAGE 
 
Western Blot protein samples were prepared by adding 50 µg of protein to an equal amount of 
sample buffer (3x sample buffer: 33.3 ml stacking buffer, 8.8 g SDS, 20 g glycerol and 
bromophenolblue in 75 ml distilled water; 850 µL 3x sample buffer + 150 µL mercaptoethanol 
was used as the working sample buffer solution). Samples were subsequently boiled for 5 
minutes before being loaded for PAGE. The samples were electrophoresed on a 10% SDS-PAGE 
(with a 4% stacking gel) at 200 V for one hour. 10 µL of protein marker (Bio-RAD Plus 
Protein™ Dual Colour Standards, CA) was included (Lane 1), with experimental samples loaded 
in the remaining lanes. After one hour, the proteins from the gel were transferred onto a PVDF 
membrane (Immobilon-P, Millipore Corporation, MA) by semi-dry electrotransfer (refer 
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Appendix 3). This membrane was used to probe for O-GlcNAc (Pierce, Rockford, IL) to assess 
degree of O-GlcNAcylation (refer Appendix 5). The amount of protein detected was analysed 
using densitometry as explained in section 2.3.4. 
 
2.6 ASSESSMENT OF HBP MODIFICATION OF PROTEINS 
 
2.6.1 Measurement of O-GlcNAcylation of BAD by fluorescence staining 
 
Immunohistochemistry can also be used to detect multiple proteins or groups simultaneously by 
tagging them with different secondary antibodies fluorescing in different wavelengths. For 
instance Bad tagged to FITC green and O-GlcNAc tagged to Texas Red can be visualised 
simultaneously and the co-localisation studies of these two tags also helps us determine if Bad 
and O-GlcNAc are present in the same proteins vicinity which gives us a measure of Bad O-
GlcNAcylation. 
 
For the purpose of fluorescence microscopy, Nunc
™
 chambered cover glass (Nalge Nunc, 
Rochester, NY) were employed. As before, H9c2 myoblasts were trypsinized, counted and ~ 
15,000 cells seeded per well in an 8-well Nunc
™
 chambered cover glass. We seeded the cells 
with 500 µL of DMEM. Subsequently, various pharmacologic treatments were administered as 
described in Section 2.1.1. 
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DMEM in wells were removed and H9c2 myoblasts were washed with 300 µL of cold PBS. 
Cells were then fixed in acetone:methanol (1:1) fixative for 10 minutes. Thereafter they were 
incubated in 5% donkey serum for 20 minutes to block non-specific binding sites. The cells were 
then incubated overnight at 4°C with a 1:50 Bad (Cell Signaling, MA) and 1:50 O-GlcNAc 
primary antibody (Piercenet, Woburn, MA) cocktail. They were then thoroughly washed with 
cold PBS and thereafter treated with a secondary antibody cocktail containing anti-rabbit FITC-
green (1:200) (Invitrogen, Carlsbad, CA) against Bad and anti-mouse Texas Red (1:200) 
(Invitrogen, Carlsbad, CA) against O-GlcNAc in the dark for 30 minutes. Since the secondary 
antibodies are fluorescent, any external light affects the signal causing background and hence 
this procedure needs to be performed in the dark. Subsequently, cells were thoroughly washed 
using cold PBS four to five times and henceforth maintained under a thin film of cold PBS for 
imaging. Cells were thereafter viewed using a Olympus CellˆR fluorescence 1 X 81 inverted 
microscope (Olympus Biosystems, Germany) using an F-view II camera (Olympus Biosystems, 
Germany) for image acquisition and CellˆR software (Olympus Biosystems, Germany) for 
processing images. The degree of Bad O-GlcNAcylation was determined using FITC and Texas 
Red filters. Bad O-GlcNAcylation was determined by measuring the area of co-localization of 
red and green stains from the images obtained, i.e. producing a yellow color. Three independent 
experiments were conducted and 4 images per experiment acquired.  
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2.6.2 Measurement of BAD O-GlcNAcylation by immunoprecipitation 
analysis 
 
Immunoprecipitation is a technique that employs protein-specific antibodies to isolate target 
proteins from the total protein fraction. The antibody-protein complexes are precipitated out of 
solution using an insoluble form of antibody-binding proteins obtained by coupling them to 
agarose or sepharose beads. 
 
H9c2 myoblasts were trypsinized, counted and ~ 300,000 cells seeded in 5 ml DMEM in T-25 
flasks (Greiner, Kremsmünster, Austria). Subsequently, various pharmacologic treatments were 
administered (described in Section 2.1.1). Following the treatment, the cells were treated with 
100 µL of freshly prepared lysis buffer (refer Appendix 1.2 for denaturing lysis buffer for 
immunoprecipitation). For rat heart tissues, the tissue pieces were homogenized and collected 
over denaturing lysis buffer.  
 
Lysates (both cellular and heart tissue) were thereafter vigorously vortexed for ~two to three 
seconds and then transferred to a microfuge tube. Due to the release of DNA the suspension 
remained viscous. The samples were then denatured by boiling for five minutes, diluted using 
900 µL non-denaturing lysis buffer (refer Appendix 1.3) and gently mixed. Triton X-100 in the 
non-denaturing buffer quenches the SDS present in the denaturing buffer. DNA contributing to 
viscosity was fragmented by pipetting the lysed suspension several times through a micropipette 
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tip until the suspension became less viscous and manageable. The suspension was thereafter 
incubated for 5 minutes at 4ºC and then immunoprecipitated. 
 
The immunoprecipitation procedure consists of two steps, i.e. a preclearing step followed by the 
actual immunoprecipitation. A quick preclearing step was performed to prevent non-specific 
binding of proteins to the beads. Here 50 µL of serum was added to the cell lysate and incubated 
for an hour on ice. This is done to allow formation of complex between serum and non-specific 
proteins. 100 µL of A-G bead slurry (Protein A/G Plus Agarose, Santa Cruz Biotechnology Inc., 
CA) was then added followed by 30 minutes incubation at 4ºC (with agitation). This allows the 
beads to bind to the complex formed between serum and non-specific proteins. The mixture was 
centrifuged (ALC PK121R Multispeed refrigerated centrifuge) at ~ 14,000 x g (4ºC) for ~10 
minutes. The pellet was thereafter discarded and the supernatant used for immunoprecipitation. 
 
About 100 µL of the protein lysate was treated with 100 µL of the O-GlcNAc antibody (1:200 
dilution) and incubated for 1 hour at 4ºC (with agitation). Thereafter, a 100 µL of bead slurry 
was added to the samples.[Note: for pipetting of the beads, pipette tips were cut off 5 mm from 
the tip to prevent breaking of the beads during pipetting and blockage of the tips.] This mixture 
was further incubated for four hours at 4ºC. The samples were then centrifuged at 14,000 x g and 
the supernatant discarded. The pellet containing the beads was then washed two to three times 
and centrifuged to obtain the maximum yield of the beads. 50 µL of sample buffer was then 
added to the beads and boiled for 5 minutes to denature proteins and to separate beads from 
precipitated proteins. This was then centrifuged at 14,000 x g for 10 minutes and the supernatant 
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was used for Western blot analysis, i.e. probed for BAD (Cell Signaling, MA). Alternatively, the 
supernatant was frozen at -80°C until later use. Likewise, an additional immunoprecipitation 
experiment was performed using the BAD antibody (same protocol followed as described for the 
O-GlcNAc antibody). Immunoprecipitated BAD was then probed for O-GlcNAc to confirm our 
findings. 
 
2.7 ASSESSMENT OF DIMERIZATION 
 
2.7.1 Co-Immunoprecipitation 
 
Co-immunoprecipitation is a useful technique to investigate protein-protein associations and to 
identify interacting partners of a target protein. It works under the same principle as 
immunoprecipitation. However, the difference being that when proteins are co-
immunoprecipitated they are isolated together with their interacting proteins. This helps us 
identify the specific interacting protein. 
 
The preparation of samples, preclearing and the preparation of the bead-sample slurry is similar 
as described in Section 2.6.2.  
 
107 
 
100 µL of the protein lysate was treated with 100 µL of BAD antibody (Cell Signaling, MA) 
(1:500 dilution) and incubated for 1 hour at 4ºC (with agitation). Thereafter, 100 µL of the bead 
slurry (Protein A/G Plus Agarose, Santa Cruz Biotechnology Inc., CA) was added to the 
samples. [Note: for pipetting of beads, the pipette tips were cut off 5 mm from the tip to prevent 
breaking of the beads during pipetting.] This mixture was further incubated for 4 hours at 4ºC. 
The samples were then centrifuged at 14,000 x g in an ALC PK121R Multispeed refrigerated 
centrifuge and the supernatant discarded. The pellet containing the beads were washed two to 
three times and centrifuged to obtain the maximum yield of beads. 50 µL of sample buffer was 
then added to the beads and boiled for 5 minutes to denature proteins and to separate beads from 
precipitated proteins. This was then centrifuged at 14,000 x g for 10 minutes and the supernatant 
used for Western blot analysis and probed for interacting proteins like Bcl-2 (Cell Signaling, 
MA). Alternatively, samples were frozen at -80°C until later use. When the blot is probed with 
various antibodies, the actual protein interacting with Bad can be known. 
 
2.7.2 Immunofluorescence microscopy – co-localization 
 
Immunohistochemistry was used to detect dimerization by tagging multiple proteins 
simultaneously with different secondary antibodies fluorescing in different wavelengths. For 
instance Bad tagged to FITC green and Bcl-2 tagged to Texas Red can be visualised 
simultaneously and the co-localisation studies of these two tags also helps us determine if Bad 
and Bcl-2 are present in close vicinity which gives us a measure of Bad-Bcl-2 dimerization. 
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The seeding and staining was done just as explained in section 2.6.1. Here, we used a rabbit-
source 1:50 Bad (Cell Signaling, MA) and a goat-source 1:50 Bcl-2 (Imgenex, San diego, CA), 
primary antibody cocktail. As for the secondary antibody, we employed an anti-rabbit FITC-
green (1:200) (Invitrogen, Carlsbad, CA) against Bad and anti-goat Texas Red (1:200) 
(Invitrogen, Carlsbad, CA) against Bcl-2. Again the viewing and co-localization was done as 
explained in section 2.6.1. 
 
2.8 A SECOND CELL-BASED MODEL OF APOPTOSIS 
 
To confirm that the changes we observed are indeed specific for our model of hyperglycaemia-
mediated apoptosis, we also employed a positive control, i.e. an alternate cell model of 
apoptosis.  For this we employed a well-established model that results in a significant degree of 
apoptosis, i.e. we treated 5.5 mM glucose cells with 50 ng/ml TNF-α [17]for 48 hours.   We 
performed our experiments ± 40 µM DON and 50 µM PUGNAc, respectively. Subsequently, 
cells were assessed for the degree of apoptosis by Hoechst nuclear staining. 
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2.9 STATISTICAL ANALYSIS 
 
Statistical analysis was performed using Graph Pad Prism (version 4). Results were expressed as 
mean ± standard error of the mean (SEM) of experiments. One-way analysis of variance 
(ANOVA) and Students-Newman-Keuls tests were performed on the data. Values were 
considered significant when p<0.05.  
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3. RESULTS 
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3.1 MODEL OF HYPERGLYCAEMIA-MEDIATED APOPTOSIS 
 
H9c2 myoblasts cultured under hyperglycaemic conditions (22 mM and 33 mM) for five days 
were assessed for apoptosis. Here hyperglycaemic conditions caused an increase of 53.1 ± 6.3% 
(n=3, p<0.01) and 54.1 ± 9.7% (n=3, p<0.01) in apoptotic nuclei in response to 22 mM and 33 
mM glucose, respectively (Figure 3.1). 
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Figure 3.1: Hoechst nuclear staining demonstrating hyperglycaemia-mediated 
apoptosis. 
A) 5.5 mM glucose, B) 22 mM glucose, C) 33 mM glucose (red arrows indicate 
apoptotic nuclei) and D) bar graphs represent the number of apoptotic nuclei counted 
using criteria stipulated in the Materials and Methods section of this thesis (Section 
2.4.1). Values are expressed as mean ± SEM (n=3). * p<0.01 vs. control. 
 
We also carried out Hoechst staining experiments with mannitol (22 mM and 33 mM mannitol) 
treated for 5 days,  in order to exclude cell death due to osmotic effects (Figure 3.2).  
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Figure 3.2: Unaltered incidence of apoptosis (Hoechst staining) in response to increasing 
mannitol concentrations. 
Bar graphs represent the number of apoptotic nuclei counted using criteria stipulated in the Materials and 
Methods section of this thesis (Section 2.4.1) n=3. 
 
To further strengthen our findings, we next assessed the degree of hyperglycaemia-induced 
apoptosis using a caspase activity assay. Here we found that hyperglycaemic conditions 
increased caspase activity by 26.4 ± 2.1% in response to 33 mM glucose (n=6, p<0.05) (Figure 
3.3). 
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Figure 3.3: Increased caspase activity in response to high glucose.  
Caspase activity was assessed using the Caspase-Glo
®
 3/7 assay method as described in the Materials 
and Methods section of the thesis (Section 2.3.2). Bar graphs represent caspase activity as measured by 
luminescence. RLU: Relative Light Units. Values are expressed as mean ± SEM (n=6). * p<0.05 vs. 
control. 
 
Encouraged by these findings we next set out to determine the stage of apoptosis and used 
Annexin-V staining to measure membrane integrity. Our data show increased staining under 
hyperglycaemic conditions (43.1 ± 4.5% vs. 5.5 mm controls). Moreover, nuclei are clearly 
condensed compared to control culturing conditions (Figure 3.4). 
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Figure 3.4: Annexin-V staining demonstrating increased apoptosis under hyperglycaemic 
conditions.  
A) 5.5 mM glucose and B) 33 mM glucose (red arrows indicate condensed nuclei) and C) bar graphs 
represent the fluorescence intensity of staining as described in the Materials and Methods section of this 
thesis (Section 2.3.3). AU: Arbitrary Units. Values are expressed as mean ± SEM (n=3). * p<0.001 vs. 
control. 
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To further confirm these data we also performed Western blotting analysis for caspase-3, a well-
described apoptotic marker. In agreement with our previous findings, hyperglycaemic conditions 
caused a significant increase in caspase-3 levels (Figure 3.5). 
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Figure 3.5: Caspase-3 Western blot analysis demonstrating hyperglycaemia-mediated apoptosis.  
A) Representative blot showing increased caspase-3 expression under hyperglycaemic conditions 
compared to matched controls (5.5 mM glucose). B) Bar graphs show densitometric representation of 
caspase-3 levels (normalized to β-actin) (* p<0.05 vs. control; n=4). AU: Arbitrary units. Values are 
expressed as mean ± SEM. 
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3.2 ROLE OF THE HEXOSAMINE BIOSYNTHETIC PATHWAY IN 
HYPERGLYCAEMIA-MEDIATED APOPTOSIS 
 
3.2.1 Inhibition of GFAT, the HBP rate-limiting step 
 
Having established an in-vitro-based method for hyperglycaemia-induced apoptosis, we next 
proceeded to test our hypothesis, i.e. the role of the HBP in this process. We began by inhibiting 
GFAT, the rate-limiting step of the HBP, by using 40 µM DON. The degree of apoptosis was 
thereafter assessed as before. We found that GFAT inhibition markedly attenuated 
hyperglycaemia-induced apoptosis, i.e. by 24.5 ± 7.9% in response to 22 mM (n=3, p<0.05 vs. 
controls) and 53.3 ± 6.2% in response to 33 mM glucose (n=3, p<0.001 vs. controls) (Figure 
3.6). 
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Figure 3.6: Inhibition of the HBP rate-limiting step (with 40 µM DON) attenuates hyperglycaemia-
mediated apoptosis.  
A) 5.5 mM glucose, B) 22 mM glucose, C) 33 mM glucose, D) 5.5 mM glucose + DON, E) 22 mM glucose 
+ DON and F) 33 mM glucose + DON (red arrows indicate apoptotic nuclei), G) bar graphs represent the 
number of apoptotic nuclei counted using criteria stipulated in the Materials and Methods section of this 
thesis (Section 2.4.1). Values are expressed as mean ± SEM (n=3). * p<0.01 vs. 22 mM glucose, ** 
p<0.001 vs. 33 mM glucose.  
 
Caspase activity assays performed in the presence of DON further supported these results. DON 
administration decreased hyperglycaemia-mediated caspase activity by 13.2 ± 3% compared to 
untreated controls (n=6, p<0.05 vs. 33 mM glucose) (Figure 3.7). 
122 
 
0
10000
20000
30000
40000
50000
*
+ 40 M  DON
5.5 mM                    33 mM
L
u
m
in
e
s
c
e
n
c
e
 (
R
L
U
)
 
Figure 3.7: Inhibition of HBP rate-limiting step attenuates hyperglycaemia-induced caspase 
activity.  
Caspase activity was assessed using the Caspase-Glo
®
 3/7 assay method as described in the Materials 
and Methods section of the thesis (Section 2.3.2). Bar graphs represent caspase activity as measured by 
luminescence. RLU: Relative Light Units. Values are expressed as mean ± SEM (n=6). * p<0.05 vs. 33 
mM glucose.  
 
We also evaluated the effects of DON on hyperglycaemia-mediated apoptosis by measuring 
Annexin-V staining. In agreement with our previous findings, DON administration showed a 
decreasing apoptotic trend though it did not show statistical significance (p=0.08 vs. 33 mM 
glucose) in response to high glucose exposure (Figure 3.8). 
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Figure 3.8: Inhibition of HBP rate-limiting enzyme attenuates Hyperglycaemia-mediated 
apoptosis.  
A) 5.5 mM glucose, B) 33 mM glucose, C) 5.5 mM glucose + DON, D) 33 mM glucose + DON 
(red arrows indicate Annexin stain fluorescence) and E) bar graphs represent the fluorescence 
intensity of staining as described in the Materials and Methods section of this thesis (section 
2.3.3). AU: Arbitrary Units. Values are expressed as mean ± SEM (n=3). * p<0.001 vs. 5.5 mM 
control.  
 
 
 
 
125 
 
 
3.2.2 Inhibition of O-GlcNAcase, enzyme cleaving off O-GlcNAc residues 
 
Assessing the effects of inhibition of O-GlcNAcase, an enzyme that removes O-GlcNAc residues 
from target proteins, by using PUGNAc, the inhibition of O-GlcNAcase should therefore result 
in higher O-GlcNAcylation of target proteins and increased apoptosis. We found increased 
apoptosis in response to PUGNAc treatment. PUGNAc administration increased apoptosis, 
although this did not reach statistical significance, i.e. p=0.07 in response to both 22 mM and 33 
mM glucose exposure. However, there was a significant increase in apoptotic nuclei for 5.5 mM 
glucose experiments treated with PUGNAc (p=0.01 vs. 5.5 mM glucose) (Figure 3.9). 
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Figure 3.9: PUGNAc treatment (50 µM) increases apoptosis under high glucose conditions.  
A) 5.5 mM glucose, B) 22 mM glucose, C) 33 mM glucose, D) 5.5 mM glucose + PUGNAc, E) 22 mM 
glucose + PUGNAc, F) 33 mM glucose + PUGNAc (red arrows indicate apoptotic nuclei) and images 
were obtained using a 10x magnification; G) bar graphs represent the number of apoptotic nuclei counted 
using criteria stipulated in the Materials and Methods section of this thesis (Section 2.4.1). Values are 
expressed as mean ± SEM (n=3). # p<0.01 vs. 5.5 mM glucose, * p=0.07 vs. 22 mM and 33 mm glucose, 
respectively.  
 
To further strengthen the Hoechst staining data, we next performed caspase activity assays in the 
presence or absence of 50 µM PUGNAc administration. PUGNAc treatment with high glucose 
increased caspase activity by 81.6 ± 5%. (n=6, p<0.001 vs. untreated 33 mM glucose) (Figure 3.10). 
Moreover, PUGNAc treatment also increased caspase activity under low glucose culturing conditions. 
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Figure 3.10: PUGNAc treatment (50 µM) increases caspase activity under hyperglycaemic 
conditions.  
Caspase activity was assessed using the Caspase-Glo
®
 3/7 assay method as described in the Materials 
and Methods section of this thesis (Section 2.3.2). Bar graphs represent caspase activity as measured by 
luminescence. RLU: Relative Light Units. Values are expressed as mean ± SEM (n=6). * p<0.001 vs. 
matching control. 
 
We also performed Annexin-V staining to confirm our earlier findings with PUGNAc treatment. 
Here PUGNAc administration under high glucose culturing conditions resulted in greater 
Annexin-V staining (50 ± 2.9% vs. untreated controls, n=3, p<0.001) thus demonstrating 
increased apoptosis (Figure 3.11). 
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Figure 3.11: Annexin-V staining showing that PUGNAc treatment increases apoptosis under high 
glucose conditions.  
A) 5.5 mM glucose, B) 33 mM glucose, C) 5.5 mM glucose + PUGNAc, D) 33 mM glucose + PUGNAc 
(red arrows indicate Annexin stain fluorescence; pink arrow indicates nuclear condensation and PI 
staining due to advanced apoptosis) and E) bar graph represents the fluorescence intensity of staining as 
described in the Materials and Methods section of this thesis (Section 2.3.3). Values are expressed as 
mean ± SEM (n=3). * p<0.001 vs. 5.5 mM glucose, # p<0.001 vs. 33 mM glucose. 
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3.3 EVALUATING THE ROLE OF OXIDATIVE STRESS IN HBP-MEDIATED APOPTOSIS 
 
3.3.1 H2DCFDA staining 
 
We began by measuring ROS levels by H2DCFDA staining. Our data show that there is an increase of 
ROS production in response to hyperglycaemia (n=3, p<0.01 vs. 5.5 mM controls) (Figure 3.12). 
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Figure 3.12: Increased ROS production in response to high glucose exposure.  
A) 5.5 mM glucose, B) 33 mM glucose (red arrow indicates ROS stain fluorescence) and C) bar graphs 
represent the fluorescence intensity of staining as described in the Materials and Methods section of this thesis 
(Section 2.4.1). AU: Arbitrary Units. Values are expressed as mean ± SEM (n=3). * p<0.01 vs. 5.5 mM control. 
 
When the cells were treated with 50 µM PUGNAc, ROS levels were increased by 22.1 ± 5.1% (n=3, 
p<0.05 vs. matching control) and 21.9 ± 3.5% (n=3, p<0.01 vs. matching controls) for both low and 
high glucose conditions, respectively (Figure 3.13). 
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Figure 3.13: Administration of PUGNAc (50 µM) increases ROS production.  
A) 5.5 mM glucose, B) 33 mM glucose, C) 5.5 mM glucose + PUGNAc, D) 33 mM glucose + PUGNAc 
(red arrow indicates ROS stain fluorescence) E) bar graph represents the fluorescence intensity of 
staining as described in the Materials and Methods section of this thesis (Section 2.4.1). AU: Arbitrary 
Units. Values are expressed as mean ± SEM (n=3). * p<0.05 vs. 5.5 mM glucose, # p<0.01 vs. 33 mM 
glucose.  
 
Having established that ROS production is increased under hyperglycaemic conditions, we next tested 
whether administration of an anti-oxidant, α-hydroxy cinnamic acid (α-OHCA), diminishes ROS 
production. We found that α-OHCA administration blunted ROS production by 18.8 ± 4.2% under 
high glucose conditions (n=3, p<0.05 vs. 33 mM glucose) (Figure 3.14). 
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Figure 3.14: Antioxidant treatment (250 µM α-OHCA) diminishes hyperglycaemia-mediated ROS 
production.  
A) 5.5 mM glucose, B) 33 mM glucose, C) 5.5 mM glucose + α-OHCA, D) 33 mM glucose + α-OHCA (red 
arrows indicate ROS stain fluorescence) and E) bar graphs represent the fluorescence intensity of 
staining as described in the Materials and Methods section of this thesis (Section 2.4.1). Values are 
expressed as mean ± SEM (n=3). * p<0.05 vs. 33 mM control. 
 
Since PUGNAc treatment increased ROS levels and α-OHCA administration had the opposite effect, 
we next set out to determine whether α-OHCA would be able to attenuate PUGNAc-mediated 
apoptosis. In light of this, these agents were co-administered and ROS levels and the degree of 
apoptosis assessed. 
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Figure 3.15: Antioxidant administration (250 µM α-OHCA) attenuates PUGNAc-mediated apoptosis.  
Bar graphs represent the number of apoptotic nuclei counted from Hoechst staining using criteria 
stipulated in the Materials and Methods section of this thesis (Section 2.4.1). Values are expressed as 
mean ± SEM (n=3). * p<0.05 vs. matched PUGNAc treatment. 
 
In agreement, we found that the PUGNAc-mediated increase in Hoechst staining and caspase 
activity was reduced when α-OHCA was co-administered (Figure 3.15 and 3.16). This 
observation was made for both low and high glucose culturing conditions. 
138 
 
0
20000
40000
60000
80000
+ 50 M PUGNAc
+ 50 M PUGNAC + 250 M -OHCA
*
*
5.5 mM                  33 mM
L
u
m
in
e
s
c
e
n
c
e
 (
R
L
U
)
 
Figure 3.16: Antioxidant (250 µM α-OHCA) treatment diminishes PUGNAc-mediated increase in caspase 
activity.  
Caspase activity was assessed using the Caspase-Glo® 3/7 assay method as described in the Materials and 
Methods section of this thesis (Section 2.3.2). Bar graphs represent caspase activity as measured by 
luminescence. RLU: Relative Light Units. Values are expressed as mean ± SEM (n=6). * p<0.001 vs. matched 
PUGNAc experiments. 
 
 
Annexin-V staining data further support these findings and indicate that this occurs during the early 
stages of the apoptotic cascade (Figure 3.17). 
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Figure 3.17: Antioxidant (250 µM α-OHCA) treatment reduces PUGNAc-mediated apoptosis.  
Bar graphs represent the fluorescence intensity of Annexin staining as described in the Materials and 
Methods section of this thesis (Section 2.3.3). Values are expressed as mean ± SEM. 
* p<0.001 vs. matched PUGNAc experiments, # p<0.001 vs. untreated 5.5 mM and 33 mM glucose. 
 
We next tested whether α-OHCA co-administration with PUGNAc attenuates ROS production as 
previously discussed. As before, antioxidant administration diminished PUGNAc-mediated ROS 
production (Figure 3.18). 
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Figure 3.18: Antioxidant (250 µM α-OHCA) treatment reduces PUGNAc-mediated ROS production.  
Bar graphs represent the fluorescence intensity of H2DCFDA staining as described in the Materials and 
Methods section of this thesis (Section 2.4.1). Values are expressed as mean ± SEM. * p<0.05 vs. 
matched PUGNAc experiment, # p<0.01 vs. matched PUGNAc experiment. 
 
The reduction in ROS by α-OHCA when co-administered with PUGNAc was also confirmed using 
flow cytometry (Figure 3.19). Here PUGNAc-mediated ROS production under low glucose culturing 
conditions (blue curve, Figure 3.19A) was markedly reduced when α-OHCA was co-administered 
(brown curve Figure 3.19A). Likewise, this observation was also made under high glucose conditions 
(Figure 3.19B). These findings are also reflected when viewed as side scatter plots (Figure 3.19C-F). 
Here α-OHCA administration under high glucose conditions shifted the fluorescence scatter to the left 
(Figure 3.19D) compared to the untreated control (Figure 3.19C) thus indicating lower ROS levels. 
When PUGNAc was administered under high glucose conditions, there is a greater fluorescence (a 
shift to the right) indicating increased ROS levels (Figure 3.19E) which are attenuated by α-OHCA co-
administration with PUGNAc (a shift to the left) (Figure 3.19F). 
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Figure 3.19: Flow cytometry demonstrating antioxidant (250 µM α-OHCA) treatment attenuating 
PUGNAc-mediated ROS production.  
A) Population fluorescence data of 5.5 mM glucose experiments (50,000 cells), B) population 
fluorescence data of 33 mM glucose (50,000 cells). FL-1 A: Alexa Fluor 488 Area. The forward scatter 
(FSC) and side scatter (SSC) shifts of C) 33  mM glucose, D) 33 mM glucose + α-OHCA, E) 33 mM 
glucose + PUGNAc, F) 33 mM glucose + α-OHCA + PUGNAc and G) bar graphs represent the 
fluorescence intensity of ROS staining as described in the Materials and Methods section of this thesis 
(Section 2.4.2). Values are expressed as mean ± SEM. * p<0.001 vs. matched PUGNAc experiment, # 
p<0.01 vs. matched PUGNAc experiment. 
 
For these set of experiments we included negative controls, i.e. cells not treated with H2DCFDA 
in order to check for background fluorescence. We also performed positive controls, i.e. by 
adding 100 µL of hydrogen peroxide (30% w/v) to samples after fluorescence measurements 
were completed. This was done to check if a sufficient amount of dye is still present in the 
sample. We found that hydrogen peroxide addition increased the fluorescence of samples, 
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shifting the curve to the right thus indicating that a sufficient amount of dye was still present in 
these samples (Figure 3.20). 
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D. 
  
Figure 3.20: Positive controls for ROS using hydrogen peroxide. 
Population fluorescence data for A) 33 mM Glucose, B) 33 mM Glucose + α-OHCA, C) 33 mM Glucose + 
PUGNAc, D) 33 mM Glucose + α-OHCA + PUGNAc. FL-1 A: Alexa Fluor 488 Area. 
 
We next confirmed these interesting findings by performing Western blot analysis. Here the 
PUGNAc-mediated increase in apoptosis and the subsequent decrease by α-OHCA co-
administration were reproduced by caspase-3, cytochrome-c and BAD peptide levels (Figure 
3.21- 3.23).  
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Figure 3.21: Increased caspase-3 peptide expression levels with HBP modulation. 
 A) Caspase-3 blot showing increased expression under hyperglycaemic conditions and PUGNAc 
administration, but decreased by antioxidant co-administration; B) Bar graphs show densitometric 
representation of caspase-3 normalized with β-actin. (* p<0.05 vs. 5.5 mM, ** p<0.01 vs. 33 mM, # p<0.01 
vs. 33 mM PUGNAc; n=4). AU: Arbitrary Units. Values are expressed as mean ± SEM. 
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Figure 3.22: Cytochrome-c Western blot analysis demonstrating HBP-mediated modulation of apoptosis.  
A) Cytochrome-c blot showing increased expression under hyperglycaemic conditions and PUGNAc 
administration, but decreased by antioxidant co-administration; B) Bar graphs show densitometric 
representation of cytochrome-c levels normalized with β-actin. AU: Arbitrary Units. Values are expressed 
as mean ± SEM (n=4). * p<0.001 vs. 5.5 mM, ** p<0.001 vs. 33 mM, # p<0.001 vs. 33 mM PUGNAc.  
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Figure 3.23: BAD Western blot analysis demonstrating HBP-mediated modulation of apoptosis.  
Representative blot showing increased BAD expression under hyperglycaemic conditions and PUGNAc 
administration, but decreased by antioxidant co-administration; B) Bar graphs show densitometric 
representation of BAD levels normalized with β-actin. AU: Arbitrary Units. Values are expressed as mean 
± SEM (n=4). * p<0.01 vs. 5.5 mM, ** p<0.001 vs. 33 mM, # p<0.001 vs. 33 mM PUGNAc. 
 
Intrigued, we next ascertained whether these novel findings would be mirrored within an in vivo 
context.  We proceeded to perform Western blot analysis on heart tissues collected from a rat model of 
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insulin resistance and hyperglycaemia. It was found that caspase-3, cytochrome-c and BAD peptide 
levels were significantly increased with the onset of insulin resistance (Figure 3.24- 3.26). 
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Figure 3.24: Evaluation of caspase-3 peptide levels in insulin resistant heart tissues. 
Heart tissues were isolated from rats fed a high fat diet for 86 days (insulin resistant) versus matched 
controls.  A) Representative caspase-3 blot for control and insulin resistant (hyperglycaemic) rat hearts; 
B) Bar graphs show densitometric analysis of caspase-3 levels normalized with β–actin. AU: Arbitrary 
Units. Values are expressed as mean ± SEM (n=6). # p<0.05 vs. control.  
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Figure 3.25: Determination of cytochrome-c peptide levels in insulin resistant heart tissues. 
Heart tissues were isolated from rats fed a high fat diet for 86 days (insulin resistant) versus matched 
controls.  A) Representative cytochrome-c blot for control and insulin resistant (hyperglycaemic) rat 
hearts; B) Bar graphs show densitometric analysis of cytochrome-c levels normalized with β–actin. AU: 
Arbitrary Units. Values are expressed as mean ± SEM (n=6). * p<0.001 vs. control. 
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Figure 3.26: Evaluation of BAD peptide levels in insulin resistant rats. 
Heart tissues were isolated from rats fed a high fat diet for 86 days (insulin resistant) versus matched 
controls.  A) Representative BAD blot for control and insulin resistant (hyperglycaemic) rat hearts; B) Bar 
graphs show densitometric analysis of BAD levels normalized with β–actin. AU: Arbitrary Units. Values 
are expressed as mean ± SEM (n=6). # p<0.05 vs. control. 
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3.4 EVALUATING THE FLUX THROUGH HBP BY O-GlcNAc MEASUREMENT 
 
3.4.1 O-GlcNAc measurement 
 
We next set out to determine the flux through HBP under hyperglycaemic conditions by 
measuring O-GlcNAc levels within the cell by fluorescence staining of O-GlcNAc. It was found 
that under hyperglycaemic conditions there is a significant increase in O-GlcNAc levels 
compared to normal glucose controls (n=3, p<0.001 vs. 5.5 mM controls) (Figure 3.27).  
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Figure 3.27: O-GlcNAc staining demonstrating increased HBP activation under hyperglycaemic 
conditions.  
A) 5.5 mM glucose and B) 33 mM glucose and C) bar graphs represent the fluorescence intensity of O-
GlcNAc staining as described in the Materials and Methods section of this thesis (Section 2.5.1). AU: 
Arbitrary Units. Values are expressed as mean ± SEM (n=3). * p<0.001 vs. control. 
 
When the cells were treated with 40 µM DON, O-GlcNAc levels decreased significantly (n=3, 
p<0.001 vs. matching control) (Figure 3.28). 
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Figure 3.28: Attenuation of O-GlcNAc staining under HBP inhibition by DON. 
A) 5.5 mM glucose, B) 33 mM glucose, C) 5.5 mM glucose + DON and D) 33 mM glucose + DON. E) bar 
graphs represent the fluorescence intensity of O-GlcNAc staining as described in the Materials and 
Methods section of this thesis (section 2.5.1). AU: Arbitrary Units. Values are expressed as mean ± SEM 
(n=3). # p<0.001 vs. 5 mM control, * p<0.001 vs. 33 mM glucose.  
 
 
When the cells were administered with 50 µM PUGNAc, there was a significant increase in the 
O-GlcNAc levels under hyperglycaemic conditions (Figure 3.29). 
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Figure 3.29: PUGNAc treatment increases O-GlcNAc levels under high glucose conditions.  
A) 5.5 mM glucose, B) 33 mM glucose, C) 5.5 mM glucose + PUGNAc, D) 33 mM glucose + PUGNAc 
and E) bar graph represents the fluorescence intensity of O-GlcNAc staining as described in the Materials 
and Methods section of this thesis (Section 2.5.1). Values are expressed as mean ± SEM (n=3). # 
p<0.001 vs. 5.5 mM glucose, * p<0.001 vs. 5.5 mM glucose, ** p<0.001 vs. 33 mM glucose. 
 
In agreement with the previous findings, co-administration of 250 µM α-OHCA with PUGNAc 
significantly decreased overall O-GlcNAcylation both under low and high glucose conditions 
(Figure 3.30 and 3.31). 
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Figure 3.30: Antioxidant mediated decrease in O-GlcNAc levels.  
A) 5.5 mM glucose, B) 33 mM glucose, C) 5.5 mM glucose + PUGNAc, D) 33 mM glucose + PUGNAc, E) 
5.5 mM glucose + PUGNAc + α-OHCA, F) 33 mM glucose + PUGNAc + α-OHCA and G) bar graph 
represents the fluorescence intensity of O-GlcNAc staining as described in the Materials and Methods 
section of this thesis (Section 2.5.1). AU: Arbitrary Units. Values are expressed as mean ± SEM (n=3). ** 
p<0.01 vs. matched untreated controls, * p<0.01 vs. PUGNAc treated experiments. 
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Figure 3.31: Western blot analysis demonstrating HBP-mediated modulation of O-GlcNAcylation.  
A) Representative O-GlcNAc blot showing increased O-GlcNAc levels under hyperglycaemic conditions 
and PUGNAc administration, but decreased by antioxidant co-administration; B) Bar graphs depict 
densitometric analysis of O-GlcNAc levels – data represent the average for 3 different protein bands 
normalized against β-actin. AU: Arbitrary Units. Values are expressed as mean ± SEM (n=4). * p<0.05 vs. 
5.5 mM, ** p<0.001 vs. 33 mM, # p<0.001 vs. 33 mM PUGNAc. 
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3.5 ELUCIDATION OF UNDERLYING MECHANISMS DRIVING THE ONSET OF 
HBP-MEDIATED CELL DEATH  
 
3.5.1 Measurement of BAD-GlcNAcylation – fluorescence microscopy  
  
We next set out to investigate the underlying mechanisms whereby cell death occurs when there 
is increased O-GlcNAcylation. Here we evaluated Bcl-2 Associated Death Promoter protein 
(BAD) as a candidate apoptotic factor and measured the O-GlcNAc modification of BAD under 
the various experimental conditions previously employed. BAD was selected because 
phosphorylation leads to its and activation of cell survival mechanisms. Studies suggest that 
phosphorylation and O-GlcNAcylation compete for identical or adjacent binding sites [1] 
thereby possibly exerting opposite effects on the protein. Hence we wanted to test if O-
GlcNAcylation of Bad had an opposite effect on the protein compared to phosphorylation. This 
was initially performed using fluorescence microscopy co-localization studies as explained in 
Section 2.6.1 (Materials and Methods). We found a significant increase in O-GlcNAcylation of 
BAD under hyperglycaemic conditions compared to low glucose conditions (Figure 3.32) (n=3, 
p<0.05 vs. 5.5 mM glucose). 
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Figure 3.32: Hyperglycaemia mediated increase in BAD O-GlcNAcylation.  
A) 5.5 mM glucose, B) 5.5 mM glucose co-localised image, C) 33 mM glucose, D) 33 mM glucose co-
localised image and E) bar graph represents the co-localisation area as described in the Materials and 
Methods section of this thesis (Section 2.6.1). Values are expressed as mean ± SEM (n=3). * p<0.05 vs. 
5.5 mM glucose 
 
Conversely treatment of cells with 40 µM DON, decreased BAD O-GlcNAcylation levels 
(Figure 3.33). 
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Figure 3.33: DON decreases hyperglycaemia-mediated increase in BAD O-GlcNAcylation.  
A) 5.5 mM glucose, B) 5.5 mM glucose co-localised image of BAD and O-GlcNAc, C) 5.5 mM + DON, D) 
5.5 mM glucose + DON co-localized image, E) 33 mM glucose, F) 33 mM glucose co-localised image, G) 
33 mM glucose + DON, H) 33 mM glucose + DON co-localised and I) bar graph represents the co-
localisation area as described in the Materials and Methods section of this thesis (Section 2.6.1). Values 
are expressed as mean ± SEM (n=3). * p<0.01 vs. 5.5 mM glucose. 
 
 
Consistent with the total O-GlcNAc results, PUGNAc treatment significantly increased BAD-
GlcNAcylation under high glucose conditions (Figure 3.34). 
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Figure 3.34: PUGNAc exacerbates BAD O-GlcNAcylation.  
A) 5.5 mM glucose, B) 5.5 mM glucose co-localised image, C) 5.5 mM + PUGNAc, D) 5.5 mM glucose + 
PUGNAc co-localised image, E) 33 mM glucose, F) 33 mM glucose co-localised image, G) 33 mM 
glucose + PUGNAc, H) 33 mM glucose + PUGNAc co-localised and I) bar graph represents the co-
localisation area as described in the Materials and Methods section of this thesis (Section 2.6.1). Values 
are expressed as mean ± SEM (n=3). * p<0.05 vs. 33 mM glucose. 
 
In agreement with our previous data, co-administration of antioxidant (α-OHCA) along with 
PUGNAc significantly decreased BAD-GlcNAcylation under hyperglycaemic conditions (Figure 
3.35). 
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Figure 3.35: Antioxidant mediated decrease in BAD-GlcNAcylation.  
A) 33 mM glucose, B) 33 mM glucose co-localised, C) 33 mM glucose + PUGNAc, D) 33 mM glucose + 
PUGNAc co-localised, E) 33 mM glucose + PUGNAc + α-OHCA, F) 33 mM glucose + PUGNAc + α-
OHCA co-localised and G) bar graph represents the fluorescence intensity of BAD-GlcNAcylation as 
described in the Materials and Methods section of this thesis (Section 2.6.1). AU: Arbitrary Units. Values 
are expressed as mean ± SEM (n=3). ** p<0.05 vs. matched untreated controls, * p<0.05 vs. PUGNAc 
treated experiments. 
 
3.5.2 Measurement of BAD-GlcNAcylation – Western blotting 
 
To confirm our BAD-GlcNAcylation microscopy data we next performed immunoblotting 
analysis. We initially immunoprecipitated O-GlcNAc modified proteins, and thereafter probed 
the membrane with a primary antibody against BAD (Figure 3.36). Subsequently, we performed 
the reverse experiment, i.e. immunoprecipitated BAD and probed the membrane with a primary 
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antibody for O-GlcNAc.   These experiments were performed using both our in vitro and in vivo 
experimental models (Figure 3.37) 
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Figure 3.36: Immunoblot demonstrating HBP-mediated BAD O-GlcNAcylation.  
A) In vitro O-GlcNAc immunoprecipitation show increased O-GlcNAc modification of BAD under 
hyperglycaemic conditions and PUGNAc administration, but decreased by antioxidant co-administration; 
B) Bar graphs depicting densitometric analysis. (n=4). # p<0.05 vs. 5.5 mM, * p<0.001 vs. 33 mM, ** 
p<0.001 vs. 33 mM PUGNAc, C) In vivo BAD O-GlcNAc blots for insulin resistant rat heart tissues (fed a 
high fat diet for 86 days) versus matched controls, D) Bar graphs show densitometric analysis of BAD-
GlcNAcylation.  # p<0.05 vs. control. Values are expressed as mean ± SEM. 
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Figure 3.37: Reverse co-precipitation demonstrating HBP-mediated BAD O-GlcNAcylation.  
 A) In vitro BAD immunoprecipitation depicting increased O-GlcNAc modification of BAD under 
hyperglycaemic conditions and PUGNAc administration, but decreased by antioxidant co-administration; 
B) Bar graphs depicting densitometric analysis (n=4). * p<0.001 vs. 33 mM, ** p<0.001 vs. 33 mM 
PUGNAc;  C) In vivo BAD O-GlcNAc blots for insulin resistant rat heart tissues (fed a high fat diet for 86 
days) versus matched controls; D) Bar graphs show densitometric analysis of BAD-GlcNAcylation (n=6).  
# p<0.05 vs. controls.  Values are expressed as mean ± SEM. 
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3.6 ELUCIDATING THE MECHANISM OF BAD-MEDIATED CELL DEATH UNDER 
HYPERGLYCAEMIC CONDITIONS 
 
To understand how O-GlcNAcylation of BAD results in increased apoptosis, we next 
investigated BAD and Bcl-2 interactions. BAD is a pro-apoptotic protein that usually dimerizes 
with the anti-apoptotic Bcl-2, thereby preventing it from performing its anti-apoptotic function. 
However, BAD is inactive in its phosphorylated form. Since BAD O-GlcNAcylation may have a 
„‟yin-yang‟‟ relationship with phosphorylation [2] and therefore probably resulting in an 
opposite functional effect, i.e. BAD activation and greater BAD-Bcl-2 dimerization, we next 
investigated whether BAD O-GlcNAcylation increased BAD-Bcl-2 dimerization under our 
experimental conditions.  
 
3.6.1 Measurement of BAD-Bcl-2 dimerization by immunoprecipitation 
 
To begin with we immunoprecipitated O-GlcNAc modified proteins, and probed the membrane 
with a primary antibody for BAD.  We observed 2 protein bands on the gel, i.e. a lower one 
corresponding to BAD (23 kDa) and a band located higher up on the gel (50 kDa) (Figure 3. 
38A).  Both these bands increased in intensity under hyperglycaemic conditions and with 
PUGNAc administration, while attenuated by antioxidant treatment.  Thus, increased BAD O-
GlcNAcylation and greater dimerization are observed when the HBP is activated.  To ascertain 
whether the higher protein band corresponds to BAD-Bcl-2 dimers, the same membrane was 
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stripped and re-probed for Bcl-2. The blot produced a higher protein band in exactly the same 
position (50 kDa) and a lower one corresponding to Bcl-2 (26 kDa) (Figure 3. 38B). Again, both 
bands increased in intensity under conditions known to induce the HBP.  Collectively this data 
show that Bcl-2 is also GlcNAcylated and that this results in greater dimerization with BAD 
under these experimental conditions.  The findings were supported by the reverse experiment, 
i.e. immunoprecipitated BAD and probed the membrane with O-GlcNAc and Bcl-2 (Figure 
3.40). Likewise, data generated by immunoprecipitation blotting experiments with tissues 
isolated from insulin resistant rat heart tissues were concordant with our in vitro blots (Figures 
3.39 - 3.41). These results parallel our in vitro data, further supporting greater BAD-Bcl-2 
dimerization under conditions where the HBP is activated.  
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Figure 3.38: Immunoblot demonstrating greater BAD-Bcl-2 dimerization under in vitro 
hyperglycaemic conditions.  
A)  Immunoblot generated by O-GlcNAc immunoprecipitation and thereafter probed for BAD; 23 kDa 
band = BAD; ~50 kDa Band = BAD-Bcl-2 dimer; B) The same immunoblot was stripped and thereafter 
probed for Bcl-2; 26 kDa band = Bcl-2. (n=4).  
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Figure 3.39: Immunoblot demonstrating greater BAD-Bcl-2 dimerization under in vivo 
hyperglycaemic conditions.  
A) Immunoblot generated by O-GlcNAc immunoprecipitation and thereafter probed for BAD; 23 kDa band 
= BAD; ~50 kDa band = BAD-Bcl-2 dimer, B) The same immunoblot was stripped and thereafter probed 
for Bcl-2; 26 kDa band = Bcl-2. (n=6).  
A.                                                                    B. 
            
               
 
 
Figure 3.40: Reverse co-precipitation demonstrating greater BAD-Bcl-2 dimerization under in vitro 
hyperglycaemic conditions.  
A)  Immunoblot generated by BAD immunoprecipitation and thereafter probed for O-GlcNAc; 23 kDa 
band = BAD; ~50 kDa Band = BAD-Bcl-2 dimer; B) The same immunoblot was stripped and thereafter 
probed for Bcl-2; 26 kDa band = Bcl-2. (n=4).  
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Figure 3.41: Reverse co-precipitation demonstrating greater BAD-Bcl-2 dimerization under in vivo 
hyperglycaemic conditions.  
A) Immunoblot generated by BAD immunoprecipitation and thereafter probed for O-GlcNAc; 23 kDa band 
= BAD; ~50 kDa band = BAD-Bcl-2 dimer, B) The same immunoblot was stripped and thereafter probed 
for Bcl-2; 26 kDa band = Bcl-2. (n=6).  
 
3.6.2 Measurement of BAD-Bcl-2 dimerization by fluorescence microscopy 
We further confirmed our Western blotting data by employing fluorescence microscopy co-
localization studies. We performed dual fluorescence in H9c2 myoblasts as explained in Section 
2.7.2 of this thesis.  In brief, we employed Texas Red and FITC-green to stain Bcl-2 and BAD, 
respectively.  An overlay of the two dyes produces a yellow color which is a marker for BAD-
Bcl-2 dimerization.  In agreement with our blotting analysis, we found increased BAD-Bcl-2 co-
localization under hyperglycaemic conditions compared to controls (Figure 3.42). Furthermore, 
PUGNAc increased BAD-Bcl-2 dimerization while antioxidant treatment significantly attenuated 
it. 
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PUGNAc + α-OHCA 
33 mM Glucose + PUGNAc + α-
OHCA – co-localized 
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Figure 3.42: Fluorescence microscopy demonstrating BAD-Bcl-2 dimerization by co-localization 
analysis using two fluorescent dyes.  
A) 5.5 mM glucose (dual staining), B) 5.5 mM glucose (co-localized), C) 33 mM glucose (dual staining), 
D) 33 mM glucose (co-localized), E) 33 mM glucose + PUGNAc (dual staining), F) 33 mM glucose + 
PUGNAc (co-localized), G) 33 mM glucose + PUGNAc + α-OHCA (dual staining), H) 33 mM glucose + 
PUGNAc + α-OHCA (co-localized), and I) bar graph represents the fluorescence intensity of BAD-
GlcNAcylation as described in the Materials and Methods section of this thesis (Section 2.7.2). AU: 
Arbitrary Units. Values are expressed as mean ± SEM (n=3). * p<0.05 vs. 5.5 mM glucose controls, ** 
p<0.05 vs. 33 mM glucose, # p<0.001 vs. 33 mM PUGNAc. 
 
In an attempt to find out the position of these proteins (Bad, Bcl-2), specifically to confirm if 
they are located near the mitochondria, we stained the mitochondria using Mitotracker Red 
(1:200) and compared it to the Bad-Bcl-2 stained cells. Interestingly, it was found that the pattern 
of mitochondrial distribution significantly matched the pattern of BAD-Bcl-2 distribution in the 
cells (Figure 3.43). 
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             A. 
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Figure 3.43: Fluorescence microscopy comparing BAD-Bcl-2 with Mitotracker Red.  
A) BAD-Bcl-2 (dual staining), B) Mitotracker Red 
 
182 
 
3.7 GFAT OVEREXPRESSION INCREASES HBP END-PRODUCT AND HBP-
MEDIATED BAD-Bcl-2 DIMERIZATION 
 
We next transfected H9c2 myoblasts (cultured in low glucose media – 5.5 mM) with a GFAT 
construct with or without a dominant negative GFAT construct. GFAT over-expression 
significantly increased overall O-GlcNAc levels as revealed by Western blotting analysis while 
co-transfection with the dominant negative GFAT construct decreased it (Figure 3.44).  
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Figure 3.44: Western blot showing increased O-GlcNAcylation with GFAT transfection.  
A) Representative O-GlcNAc blot showing increased O-GlcNAc levels in GFAT transfection but 
decreased by dominant negative GFAT transfection; B) Bar graphs depict densitometric analysis of O-
GlcNAc levels – data represent the average for 3 different protein bands normalized against β-actin. AU: 
Arbitrary Units. Values are expressed as mean ± SEM (n=4). * p<0.001 vs. control,  
** p<0.01 vs. GFAT. 
 
As before, immunoprecipitation of O-GlcNAcylated proteins and subsequent probing for BAD  
revealed 2 bands, i.e.  50 kDa and  23 kDa corresponding to BAD-Bcl-2 dimers and BAD, 
respectively. When the membrane was stripped and re-probed with Bcl-2, the 50 kDa band was 
observed together with a 26 kDa band corresponding to Bcl-2 (Figure 3.45).  
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Figure 3.45: Immunoblot demonstrating greater BAD-Bcl-2 dimerization with GFAT transfection.  
A)  Immunoblot generated by O-GlcNAc immunoprecipitation and thereafter probed for BAD; 23 kDa 
band = BAD; ~50 kDa Band = BAD-Bcl-2 dimer; B) The same immunoblot was stripped and thereafter 
probed for Bcl-2; 26 kDa band = Bcl-2. (n=4).  
 
We confirmed these results by performing the reverse experiment.  For this BAD was 
immunoprecipitated using standard methods and thereafter probed for O-GlcNAc.  As before, we 
observed similar banding patterns as before (Figure 3.46). 
 
 
 
 
 
BAD 
BAD- Bcl-2 
 Bcl-2 
185 
 
 
A.                                                                 B. 
     
  
 
 
Figure 3.46: Immunoblot demonstrating greater BAD-Bcl-2 dimerization under in vitro 
hyperglycaemic conditions.  
A)  Immunoblot generated by BAD immunoprecipitation and thereafter probed for O-GlcNAc; 23 kDa 
band = BAD; ~50 kDa Band = BAD-Bcl-2 dimer; B) The same immunoblot was stripped and thereafter 
probed for Bcl-2; 26 kDa band = Bcl-2. (n=4).  
 
3.8 A SECOND CELL-BASED MODEL OF APOPTOSIS 
 
We tested whether the novel HBP-mediated death pathway identified in this study would also be 
activated in a second model of apoptosis.  We employed a TNF-α-mediated cell model of 
apoptosis previously described (Section 2.8). Since there is no hyperglycaemia and oxidative 
stress associated with this model, we predicted that the HBP would not be triggered and that 
apoptosis would occur via non-HBP-mediated pathways.  In response to 50 ng/ml TNF-α 
BAD 
BAD- Bcl-2 
 Bcl-2 
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treatment for 48 hours, it was found that both DON and PUGNAc treatment did not significantly 
increase or decrease the degree of apoptosis (Figure 3.47).  
A.                                                              B. 
 
            
 
                     
       
       C.                                                                  D. 
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Figure 3.47: Hoechst nuclear staining positive control. 
A) 5.5 mM glucose, B) 5.5 mM glucose + TNF-α, C) 5.5 mM glucose + TNF-α + DON, D) 5.5 mM + TNF-α 
+ PUGNAc (red arrows indicate apoptotic nuclei,) and E) bar graphs represent the number of apoptotic 
nuclei counted using criteria stipulated in the Materials and Methods section of this thesis (Section 2.3.1). 
Values are expressed as mean ± SEM (n=3). * p<0.001 vs. 5.5 mM control.  N=4. 
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4. DISCUSSION 
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Introduction 
Type 2 diabetes and related metabolic perturbations are closely linked to cardiovascular 
complications [1-3]. In support, several studies demonstrate increased risk for CVD-related 
mortality under hyperglycaemic conditions [4-6]. Hyperglycaemia-mediated flux through 
glucose utilizing pathways, e.g. the HBP is robustly implicated in the development of insulin 
resistance, type 2 diabetes [7] and CVD [8]. However, the precise mechanisms mediating these 
processes are unclear. In light of this, we hypothesized that hyperglycaemia-mediated activation 
of the HBP increases O-GlcNAcylation of apoptotic proteins resulting in myocardial apoptosis, 
thereby contributing to contractile dysfunction and cardiovascular disease. The main findings of 
this study are: 1) Hyperglycaemia-mediated activation of the HBP mediates myocardial 
apoptosis; 2) Oxidative stress plays a crucial role in hyperglycaemia/HBP-mediated apoptosis; 
and 3) Identification of a novel apoptotic pathway in the heart involving HBP-induced O-
GlcNAcylation of BAD. 
 
4.1 HYPERGLYCAEMIA-MEDIATED ACTIVATION OF THE HBP MEDIATES 
MYOCARDIAL APOPTOSIS 
 
Previous studies showed that hyperglycaemia could trigger apoptosis [9]. For instance, elevated 
glucose culturing conditions result in greater glucose oxidation, increased superoxide production 
[10] and DNA damage. PARP is subsequently activated [11] resulting in apoptosis [12]. 
Likewise, hyperglycaemia may result in cytochrome-c release thereby activating caspase-3 [9] 
and apoptosis. In agreement, high glucose treatments (15 mM) caused a significant degree of 
191 
 
apoptosis in human mononuclear cells [13].  Phaeochromocytoma cells from rat adrenal medulla 
displayed increased DNA fragmentation, a high Bax/Bcl-2 ratio causing more mitochondrial 
membrane disruption and increased caspase-8, caspase-9 and caspase-3 levels when exposed to 
hyperglycaemic conditions [14]. Furthermore, a significant increase in apoptosis was found in 
human umbilical vein endothelial cells exposed to 30 mM glucose for 72 hours [15]. Also, it has 
been shown that trypsin digests of retinal micro capillaries under hyperglycaemic conditions 
showed a 2.5 fold upregulation of apoptotic regulatory genes like BAD, Bax, etc. [16]. 
Conversely, microarray studies have shown a decrease in apoptotic gene expression in diabetic 
rats [17, 18]. We believe that differences in published data may be due to the stage of disease 
progression and experimental model employed. For example, the abovementioned microarray 
study was performed at a relatively early time point during the progression towards full-blown 
diabetes, while others done at later time points may yield different findings.  
 
Despite progress in this field not many studies have investigated hyperglycaemia-mediated 
apoptosis in the heart. In light of this, we established an in vitro model of hyperglycaemia-
mediated apoptosis by employing rat cardiac-derived H9c2 myoblasts. Here we initially 
administered 22 and 33 mM glucose, respectively, for five days versus 5.5 mM controls. This 
was in line with previous cell-based studies which employed similar glucose concentrations [9, 
15, 19, 20]. Both concentrations caused a significant degree of apoptosis, i.e. as revealed by 
Hoechst and Annexin-V staining and increased caspase activity. Moreover, we found increased 
expression of caspase-3, BAD and cytochrome-c under hyperglycaemic conditions. To establish 
proof-of-concept, we subsequently focussed on the 33 mM concentration (more pronounced 
effects). We are confident that our in vitro data are robust since a) 33 mM mannitol showed no 
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significant apoptosis thus ruling out osmotic effects and proving that apoptosis observed in our 
model is due to hyperglycaemia per se; and b) in vitro findings were paralleled in hearts of a rat 
model of insulin resistance and hyperglycaemia. 
 
Previous studies show that HBP activation results in apoptosis [21, 22]. For example, increased 
O-GlcNAcylation of p53 (a tumor suppressor protein), leads to greater synthesis of angiotensin-
II, thereby causing apoptosis. Here enzymatic p53 glycosylation leads to angiotensin II formation 
which binds to AT1 receptors. This post-translational modification increases p53 stability, 
thereby prolonging activation of angiotensin II and causing apoptosis. Bax expression levels 
were also elevated leading to increased apoptosis and cytochrome-c release [23]. Glycosylation 
may also interfere with the proteolysis system of the cell, i.e. by O-GlcNAcylation of 
proteosomes. This could result in ineffective proteolysis of proteins including pro-apoptotic 
proteins such as BAD and thereby leading to greater apoptosis [24]. However, it is unclear 
whether hyperglycaemia-mediated HBP activation causes apoptosis in the heart. Our data show a 
significant increase in total O-GlcNAcylation of cardiac proteins as demonstrated by 
immunofluorescence microscopy, Western blotting analysis and GFAT overexpression. This 
elevation was closely linked to higher incidence of apoptosis. Together these data show 
increased HBP flux under hyperglycaemic conditions is associated with a higher degree of 
apoptosis. In agreement, elevated O-GlcNAcylation of proteins and apoptosis were observed in 
in vivo heart tissue of insulin resistant/hyperglycaemic rats. 
  
193 
 
To further investigate these interesting findings, we next attenuated HBP flux by inhibiting 
GFAT, the rate-limiting enzyme of this pathway. DON is an analogue of glutamine that inhibits 
glutamine-requiring enzymes e.g. (GFAT) and is widely used as a GFAT inhibitor [25]. As 
predicted, we found that DON administration resulted in decreased cardiac O-GlcNAcylation of 
proteins and attenuated apoptosis when compared to hyperglycaemic conditions. We also 
inhibited O-GlcNAcase thereby increasing the O-GlcNAcylation of target proteins. For this 
purpose, we employed PUGNAc, an inhibitor of N-acetylglucosaminidase, that is routinely used 
to inhibit O-GlcNAcase and thereby increase O-GlcNAcylation of proteins [26]. We found that 
PUGNAc treatment increased O-GlcNAcylation of proteins in cardiac myoblasts. In parallel, 
myoblast apoptosis was increased. Collectively the data therefore strongly supporting a role for 
the HBP in hyperglycaemia-induced apoptosis in cardiac myoblasts. 
 
However, Chatham et al. proposed that HBP and O-GlcNAcylation trigger cardioprotective 
mechanisms thereby enhancing cell survival [27]. For example, they found that PUGNAc 
treatment resulted in improved survival of monkey kidney cells in response to thermal treatments 
[28]. GFAT inhibition also resulted in the opposite effect, i.e. decreased O-GlcNAcylation and 
increased cell death [29]. Also, activation of HBP in perfused hearts (glucosamine or glutamine 
treatment) before an ischaemic insult resulted in elevated O-GlcNAc levels, improved contractile 
function and decreased tissue injury after reperfusion [30, 31]. Likewise, others found that 
inhibition of O-GlcNAcase significantly augmented O-GlcNAc levels and reduced post-hypoxic 
cell death in isolated cardiac myocytes [8]. This study also found increased post-hypoxic cell 
death and reduced mitochondrial membrane potential recovery when O-GlcNAcase expression 
was elevated.  
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How could activation of the same pathway result in opposite effects? We propose that different 
proteins are likely to be O-GlcNAcylated in the experimental models employed. It is likely that 
glucosamine and glutamine treatment “tagged” (i.e. O-GlcNAcylated) anti-apoptotic proteins 
while high glucose treatments tagged pro-apoptotic proteins. This is an intriguing question that 
requires further investigation, i.e. why and how does the cell know which proteins to target for O-
GlcNAcylation within a particular context, e.g ischaemic-reperfusion or hyperglycaemia. These 
questions are currently vigorously pursued in our laboratory. 
 
4.2 OXIDATIVE STRESS PLAYS A CRUCIAL ROLE IN HYPERGLYCAEMIA/HBP-
MEDIATED APOPTOSIS 
 
The involvement of oxidative stress in cell damage under hyperglycaemic conditions is well 
documented. For instance, Brownlee‟s laboratory proposed that hyperglycaemia increases the 
inner mitochondrial membrane potential, resulting in greater mitochondrial superoxide 
production and DNA damage [10, 32, 33]. Subsequently, PARP is released as a DNA reparative 
mechanism. But PARP also inhibits GAPDH thereby resulting in the accumulation of upstream 
glycolytic metabolites like fructose-6-phosphate that may increase HBP flux [11].  
 
We measured overall ROS production in our model of hyperglycaemia-induced apoptosis by 
employing fluorescence microscopy and flow cytometry. Our results show markedly elevated 
ROS levels in response to hyperglycaemia at both single cellular (microscopy) and cell 
population (flow cytometry) levels. Hyperglycaemia is generally known to induce superoxide 
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production [34] and we speculate the same for our model. In support, others found that 
hyperglycaemia-induced ROS production in renal cells mediates apoptosis and contributes to 
diabetic nephropathy [35]. Moreover, diabetic rats display increased expression of genes 
involved in oxidative stress and apoptosis [36], while H9c2 myoblasts exposed to high glucose 
levels exhibit decreased expression of heat shock protein 27, resulting in oxidative stress and 
apoptosis [37].  
 
We strengthened our hypothesis by including the antioxidant 4-OHCA that acts by inhibiting 
pyruvate transport into mitochondria, thereby reducing mitochondrial ROS production. As 
expected, antioxidant treatment attenuated ROS levels observed under both hyperglycaemic 
conditions and with PUGNAc treatment. In parallel, antioxidant administration diminished HBP-
mediated cardiac O-GlcNAc levels and apoptosis. 
 
We also found that treatment with PUGNAc alone increased ROS levels. This raises the 
question: why would higher O-GlcNAcylation trigger increased ROS production? We speculate 
that there may be increased O-GlcNAcylation of anti-oxidant proteins like superoxide dismutase 
(SOD) thereby inactivating it and decreasing antioxidant capacity. It is also possible that 
antioxidant protein expression may be decreased due to O-GlcNAcylation and inactivation of 
transcription factors that usually induce expression of these genes. It may also be possible that O-
GlcNAcylation of antioxidant proteins such as SOD could render them less stable and therefore 
more prone to proteosomal degradation. These interesting concepts need to be investigated. 
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Taken together our results strongly support the concept that increased ROS production and 
greater HBP flux orchestrate hyperglycaemia-mediated apoptosis in cardiac myoblasts [32].   
 
4.3 IDENTIFICATION OF A NOVEL APOPTOTIC PATHWAY IN THE HEART 
INVOLVING HBP-INDUCED O-GLCNACYLATION OF BAD 
 
Since we found increased apoptosis (↑ cytochrome-c release) in our hyperglycaemic cell model 
and insulin resistant heart tissues, we explored underlying mechanisms mediating this process. 
Cytochrome-c is released as a result of mitochondrial membrane disruption which is most 
commonly caused by apoptotic protein dimers such as Bax and Bak [38]. It has been documented 
that hyperglycaemia induces increased Bax expression and apoptosis [39]. Moreover, reduced 
apoptotic rates were observed in transgenic Bax
/
(Bax-deficient) mice exposed to 
hyperglycaemia [39] indicating that Bax does indeed play a major role in the apoptotic cascade.  
 
But, how does Bax cause apoptosis? This occurs via a pathway involving BAD (Bcl-2 associated 
death promoter protein) and Bcl-2. BAD in its dephosphorylated form usually forms a 
heterodimer with Bcl-2 or Bcl-xL (Figure 4.1). Bcl-2/Bcl-xL are anti-apoptotic proteins present 
on the mitochondrial membrane to prevent apoptosis by heterodimerizing with Bax and Bak to 
prevent them from forming homodimers since Bax:Bax and Bak:Bak homodimers usually insert 
into the mitochondrial membrane causing cytochrome-c release [40].   
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Figure 4.1: Representation showing Bad mediated apoptosis.  
Step 1: Bad phosphorylation renders it inactive. Step 2: Unphosphorylated Bad dimerizes with Bcl-2 
forming a heterodimer. Step 3: Reduced Bcl-2 dimerization with Bax. Step 4: Free Bax now forms 
homodimers leading to disruption of the mitochondrial membrane, thereby inducing apoptosis. 
 
However, when BAD is dephosphorylated, it binds to Bcl-2 and prevents the Bcl-2 mediated 
sequence of events, thereby resulting in apoptosis. Conversely, when BAD is phosphorylated its 
binding affinity to Bcl-2 is decreased, meaning formation of Bax:Bcl-2 dimers and greater cell 
survival. Hence the phosphorylation status of BAD plays a crucial role in cell survival. Several 
upstream regulators are implicated in determining the phosphorylation status of BAD, including 
PIM2 kinase [41], C-Raf kinase [42], p38 MAP kinase [24], p90-Rsk-1 [43], PKA and PKB.  
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What happens when BAD is O-GlcNAcylated? Previous work have shown that a “yin-yang” 
relationship may prevail between phosphorylation and O-GlcNAcylation, i.e. competition 
between phosphorylation and O-GlcNAcylation for the same site or closely located sites on 
target proteins [44]. Under circumstances of increased HBP flux, there is greater O-
GlcNAcylation of BAD thus likely decreasing its phosphorylation status. We propose that O-
GlcNAcylation of BAD occurs in the near vicinity or at the same site(s) as BAD 
phosphorylation, resulting in reduced access to upstream kinases.  As a result, BAD remains in a 
dephosphorylated state thereby triggering apoptosis.  In support of this concept, glucosamine 
treatment of pancreatic β–cells resulted in increased O-GlcNAcylation of Akt and reduced 
phosphorylation at Ser473 [45], i.e. O-GlcNAcylation „‟out-competing‟‟ phosphorylation.  Since 
the Akt signaling pathway results in phosphorylation of BAD [46] these findings suggest that 
defects in Akt activation may eventually enhance apoptosis.  Alternatively, glycosylation may 
also interfere with the proteolysis system of the cell, i.e. by O-GlcNAcylation of proteasome. 
This could result in ineffective rate of proteolysis of proteins including pro-apoptotic proteins 
such as BAD and thereby leading to greater apoptosis [24].  Another possibility is that O-
GlcNAcylation may directly alter BAD‟s activity and thereby trigger apoptosis.  These 
interesting possibilities require further investigation. 
We explored this mechanism in both our in vitro and in vivo models. We initially measured the 
degree of BAD O-GlcNAcylation, followed by the determination of BAD:Bcl-2 dimer 
formation. Dual fluorescence staining and co-localization studies revealed that there is 
augmented O-GlcNAcylation of BAD under hyperglycaemic conditions. In agreement, BAD O-
GlcNAcylation was attenuated by HBP inhibition and increased by PUGNAc treatment. 
Moreover, BAD O-GlcNAcylation was attenuated when an antioxidant was co-administered thus 
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supporting our hypothesis that oxidative stress plays a vital role in this process. These in vitro 
results were well supported by data generated from our in vivo rat model of insulin resistance.  
 
Our in vitro and in vivo immunoblotting and co-localization data reveal that BAD does indeed 
form a dimer with Bcl-2.Dimer formation increases under hyperglycaemic conditions and with 
PUGNAc treatment, suggesting that O-GlcNAcylation maintains BAD in its active form, i.e. 
dimerizing with Bcl-2 and resulting in increased apoptosis (Figure 4.1). 
 
Figure 4.2: Representation showing how increased Bad O-GlcNAcylation triggers apoptosis.  
Step 1: Hyperglycaemia-induced increased HBP flux results in increased O-GlcNAcylation of Bad. Step 2: 
Higher O-GlcNAcylation leads to reduced Bad phosphorylation. Step 3: Increased dimerization of O-
GlcNAcylated Bad with Bcl-2. Step 4: Reduced Bcl-2 dimerization with Bax. Step 5: Free Bax now forms 
homodimers leading to disruption of the mitochondrial membrane, thereby inducing apoptosis. 
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Moreover, antioxidant treatment blunted these effects.  Our data suggest that there is increased 
BAD O-GlcNAcylation and increased BAD:Bcl-2 dimerization under hyperglycaemic 
conditions. We propose that increased dimer formation plays a crucial role in hyperglycaemia-
mediated apoptosis observed in both our experimental models. It is predicted that increased 
myocardial apoptosis will result in contractile dysfunction. Evaluation of heart functional 
measurements fell outside the scope of this study and thesis and is currently being pursued by 
others in our laboratory. 
 
Limitations of the study 
1)  no controls for immunoprecipitation, e.g. IgG; 2) additional reverse immunoprecipitation of 
Bcl-2 and probing for BAD was not done; 3)  HbA1c levels  in the rat model were not available 
to confirm longstanding hyperglycaemia; and 4) BAD phosphorylation was not measured but is a 
crucial parameter to determine in order to observe the yin-yang relation between phosphorylation 
and O-GlcNAcylation.  These are ongoing studies in our laboratory. 
 
In summary, we identified a novel pathway (for the first time as far as we are aware) whereby 
hyperglycaemia results in greater oxidative stress, increased BAD O-GlcNAcylation and BAD-
Bcl-2 dimer formation, thereby mediating HBP-induced myocardial apoptosis. It is likely that 
this maladaptive pathway may be triggered with repetitive hyperglycaemic spikes in pre-diabetic 
patients and/or in diabetic patients with chronically elevated glucose levels. We propose that 
these factors converge to contribute to contractile dysfunction within this context, i.e. the 
diabetic cardiomyopathy. Our work offers unique possibilities for novel therapeutic interventions 
that could play a significant role to help attenuate the growing global burden of diabetes and 
CVD. 
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FUTURE WORK 
- Determine whether there are other proteins linked to the two dimerizing proteins i.e. Bad 
and Bcl-2 
- Employ streptozotocin-induced diabetic rodents to test for similar effects in a type 1 
model of diabetes 
- Employ 2-deoxyglucose as a control and test for its effects 
- Employ cardiac-specific transgenic GFAT knock-out mice to assess potential  
cardioprotective effects 
- Evaluate whether similar findings obtained when using  isolated adult cardiomyocytes as 
an experimental system. 
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Appendix 1 
1.1 Modified RIPA Buffer: 
A 100 ml modified RIPA buffer contains: 
- 50 mM Tris-HCl (790 mg of Tris in 75 ml distilled water and 900 mg of NaCl and pH 
made 7.4 using HCl) 
- 10 ml of 10% NP-40 [final concentration 1%] 
- 2.5 ml of 10% sodium deoxycholate [final concentration 0.25%] 
- 1 ml of 100 mM EDTA pH 7.4 [final concentration 1 mM] 
- Protease inhibitors  
 500 µL of 200 mM phenylmethylsulfonyl fluoride (PMSF) [final 
concentration 1 mM] 
 100 µL of Leupeptin (1 mg/ml water) [final concentration 1 µg/ml] 
 80 µL of SBT1 (5 mg/ml water) [final concentration 4 µg/ml] 
 100 µL of Benzamidine (1 M) [final concentration 1 mM] 
- Protein phosphatase inhibitors 
 500 µL of 200 mM activated sodium orthovanadate (Na2VO3) [final 
concentration 1 mM] 
 500 µL of 200 mM NaF [final concentration 1mM] 
- 1 ml Triton X-100 
This buffer is then made up to a final volume of 100 ml with distilled water and stored at -
20°C.  
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1.2 Denaturing Lysis Buffer for Immunoprecipitation: 
The RIPA buffer for immunoprecipitation was made up separately containing: 
      - 50 mM Tris HCl 
      - 150 mM NaCl 
      - 1% NP-40 
      - 0.5% Na deoxycholate 
      - 0.1% SDS 
The protease inhibitors (PMSF- 50 µg/ml, Aprotonin- 1µg/ml) are added just before use. 
1.3 Non-denaturing Lysis Buffer for Immunoprecipitation: 
The non-denaturing lysis buffer contained: 
        - 20 mM Tris HCl 
        - 137 mM NaCl 
        - 10% glycerol 
        - 1% Triton X-100 
        - 2 mM EDTA 
The protease inhibitors (PMSF- 50 µg/ml, Aprotonin- 1µg/ml) are added just before use. 
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Appendix 2 
Bradford protein quantification method: 
Bradford reagent 
- 500 mg of Coomassie Brilliant Blue G in 250 ml of 95% ethanol 
- 500 ml of phosphoric acid  
This is made up to 1 litre using distilled water, filtered and stored at 4°C. 
Working solution: 
The Bradford stock is diluted in 1:5 ratio using distilled water, filtered and used for protein 
quantification. 
Bradford method: 
- BSA (1 mg/ml) is diluted in a 1:4 ratio using distilled water. 
- A protein standard with varying protein concentrations is prepared as follows 
               BSA (µL)    BSA concentration (µg) Volume of distilled water  
(µL) 
                  0                 Blank                     100 
                 10                   2                       90 
                 20                   4                       80 
                 40                   8                       60 
                 60                  12                       40 
                 80                  16                       20 
                100                  20                         0 
                  5    Unknown protein sample                       95 
 
- To all these protein and BSA standards, 900 µL of Bradford working solution is added 
and vortexed gently. 
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- Samples were allowed to stand for ~ 5 minutes. 
- The absorbancies of each sample was read using a spectrophotometer at 595 nm. (If the 
protein absorbancies fall outside the protein standard, the proteins must be diluted with 
RIPA buffer and reading taken again). 
- The absorbancies were then plotted to construct a linear plot for the standards. Thereafter 
the amounts of protein in unknown samples were quantified in relation to the linear 
standard plot. 
Sample preparation: 
- A stock solution of sample buffer containing 850 µL sample buffer and 150 µL 
mercaptoethanol is prepared. 
- A volume of sample buffer equivalent to 1/3 final volume of the sample if added (under 
the fume hood). 
- The appropriate amounts of proteins are added to each tube calculated previously. 
- Tiny holes are punched on the lids of microfuge tubes (containing the prepared sample) 
and placed in boiling water for about 5 minutes. 
- The tubes are then briefly spun in a table top centrifuge. 
- Samples can now be used for Western blot analysis or alternatively be stored at -80°C for 
later use. 
- If samples are stored at -80°C, they must be boiled for 5 minutes in boiling water and 
shortly centrifuged before being used for western blotting analysis. 
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Appendix 3 
 
Electrotransfer of proteins: 
 
Solutions for Electrotransfer: 
Anode Buffer 1: 
          0.3 M Tris-base, pH 10.4 
          20% methanol 
Anode Buffer 2: 
          25 mM Tris-base, pH 10.4 
          20% methanol 
Cathode Buffer: 
          25 mM Tris-base 
          40 mM ε-aminohexanoic acid ( pH 9.4) 
          20% methanol 
 
Electrophoresed proteins were subsequently transferred onto a PVDF membrane (Immobilon-P, 
Millipore Corporation, MA, USA) by electrotransfer on a semidry transfer apparatus (Bio-
RAD® Semi-Dry Transfer Cell, Bio-RAD Laboratories, California, USA)., Eight Whatmann 
3MM papers and one PVDF membrane were cut to size of the gel. The membrane was first 
soaked in methanol for 15 seconds, washed with distilled water and then soaked in anode buffer 
2.  
Three Whatmann papers were well soaked in anode buffer one and placed onto the anode plate 
of the transfer apparatus. The papers were rolled dry to make sure that there were no bubbles. A 
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single Whatmann paper was soaked in anode buffer two and placed over the other papers in the 
apparatus. The PVDF membrane, soaked in anode buffer two, was then placed over the 
Whatmann papers. The electrophoresed gel soaked in anode buffer two was placed on top of this 
and rolled dry. Finally, the remaining four Whatmann papers were soaked in cathode buffer and 
placed over the gel and rolled dry. The cathode plate of the apparatus is then placed over the gel 
sandwich, closed and run at 15 volts (current of 0.5 A) for one hour. After the transfer, the 
protein in the membrane was fixed by placing it in methanol for a few seconds. 
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Appendix 4 
Detection of proteins (Western blots): 
Probing the membrane 
Non-specific binding in the membrane is blocked overnight at 4°C with 5% milk solution (5 g fat 
free milk powder in 100 ml TBS Tween). After blocking, the membrane is washed in 1x TBS 
containing 0.1% Tween (TBS-Tween) and thereafter incubated overnight at 4°C with the 
primary antibody investigated. We employed a 1:1000 dilution of the primary antibody. The 
membrane was then thoroughly washed in TBS-Tween and incubated for one hour at room 
temperature with secondary anti-mouse HRP monoclonal antibody (1:4000). The membrane was 
then washed three to fourtimes in TBS-Tween and finally once in plain 1x TBS and developed. 
 
Developing the membrane 
The membrane was treated with 2.5 ml KPL LumiGLO..... (KPL Inc., Maryland, USA) for one 
minute and making sure that the reagent is evenly distributed over the membrane. It was then 
dried on tissue paper, placed between transparencies and was then developed in a dark room. A 
developing film (Hyperfilm, Amersham, Buckinghamshire, UK) was placed over the sandwiched 
membrane and exposed for 5-10 minutes. The film was then developed by placing it in 
developing solution for 5 minutes followed by 15 seconds in a fixative. This film was then used 
for densitometric analysis.  
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Appendix 5 
 
O-GlcNAc Western blot detection: 
 
Note: This procedure is described as per the manufacturer‟s instructions of the O-GlcNAc 
Western blot detection kit (Pierce, Catalogue number: 24565, Rockford, Illinois, USA) using the 
reagents supplied with the kit. 
Buffers required for O-GlcNAc Western blot detection: 
Wash Buffer: 
One pack of BuPH
™
 Phosphate Buffer Saline (PBS) is reconstituted in 500 ml ultrapure water 
and 2.5 ml of 10% Tween
®
-20 to a final concentration of ~ 0.05 % is added. 
Blocking Buffer: 
The 10x dilution buffer provided in the kit is diluted to 1x using the previously prepared wash 
buffer. 
Goat Anti-Mouse IgM- HRP Conjugate (Secondary antibody): 
A 1 mg/ml stock of the secondary antibody is prepared by reconstituting the antibody in 75 µL 
ultrapure water. This is then divided into 6 µL aliquots followed by the addition of an equal 
volume of glycerol. The final concentration of each aliquot is 0.5 mg/ml and aliquots were stored 
at -20°C. 
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O-GlcNAc detection: 
After electrotransfer of proteins onto the PVDF membrane, the non-specific sites were blocked 
overnight at 4°C using the supplied blocking buffer. The membrane was then treated with the 
primary O-GlcNAc antibody (1:5000 dilution in blocking buffer) and incubated overnight at 
4°C. Thereafter, it was thoroughly washed in wash buffer and exposed to secondary antibody 
(1:5000 dilution in blocking buffer) for one hour at room temperature with gentle shaking. The 
membrane was thoroughly washed and developed. 
Developing the membrane 
The membrane was then treated for 5 minutes with detection reagent (5 ml of Stable Peroxide 
Solution and 5 ml of Luminol/Enhancer supplied with the kit) and placed between 
transparencies. This was then developed in a dark room. A developing film (Hyperfilm, 
Amersham, Buckinghamshire, UK) was placed over the sandwiched membrane and exposed for 
~ 7 seconds. The film was placed in developing solution for ~ 30 seconds and then in a fixative 
for 15 seconds. Densitometric analysis was performed as described before. 
 
 
